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A B S T R A C T
Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying
tissue, or both. A range of treatments with antimicrobial properties, including impregnated dressings, are widely used in the treatment
of pressure ulcers. A clear and current overview is required to facilitate decision making regarding use of antiseptic or antibiotic therapies
in the treatment of pressure ulcers. This review is one of a suite of Cochrane reviews investigating the use of antiseptics and antibiotics
in different types of wounds. It also forms part of a suite of reviews investigating the use of different types of dressings and topical
treatments in the treatment of pressure ulcers.
Objectives
To assess the effects of systemic and topical antibiotics, and topical antiseptics on the healing of infected and uninfected pressure ulcers
being treated in any clinical setting.
Search methods
In October 2015 we searched: the Cochrane Wounds Specialised Register, the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library), Ovid MEDLINE, Ovid MEDLINE (In-Process & Other Non-Indexed Citations), Ovid EMBASE,
and EBSCOCINAHL Plus.We also searched three clinical trials registries and the references of included studies and relevant systematic
reviews. There were no restrictions based on language or date of publication or study setting.
Selection criteria
Randomised controlled trials which enrolled adults with pressure ulcers of stage II or above were included in the review.
Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction.
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Main results
We included 12 trials (576 participants); 11 had two arms and one had three arms. All assessed topical agents, none looked at systemic
antibiotics. The included trials assessed the following antimicrobial agents: povidone iodine, cadexomer iodine, gentian violet, lysozyme,
silver dressings, honey, pine resin, polyhexanide, silver sulfadiazine, and nitrofurazone with ethoxy-diaminoacridine. Comparators
included a range of other dressings and ointments without antimicrobial properties and alternative antimicrobials. Each comparison
had only one trial, participant numbers were low and follow-up times short. The evidence varied from moderate to very low quality.
Six trials reported the primary outcome of wound healing. All except one compared an antiseptic with a non-antimicrobial comparator.
There was some moderate and low quality evidence that fewer ulcers may heal in the short term when treated with povidone iodine
compared with non-antimicrobial alternatives (protease-modulating dressings (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.62
to 0.98) and hydrogel (RR 0.64, 95% CI 0.43 to 0.97)); and no clear difference between povidone iodine and a third non-antimicrobial
treatment (hydrocolloid) (low quality evidence). Pine resin salve may heal more pressure ulcers than hydrocolloid (RR 2.83, 95% CI
1.14 to 7.05) (low quality evidence). There is no clear difference between cadexomer iodine and standard care, and between honey a
combined antiseptic and antibiotic treatment (very low quality evidence).
Six trials reported adverse events (primary safety outcome). Four reported no adverse events; there was very low quality evidence from
one showing no clear evidence of a difference between cadexomer iodine and standard care; in one trial it was not clear whether data
were appropriately reported.
There was limited reporting of secondary outcomes. The five trials that reported change in wound size as a continuous outcome did not
report any clear evidence favouring any particular antiseptic/anti-microbial treatments. For bacterial resistance, one trial found some
evidence of more MRSA eradication in participants with ulcer treated with a polyhexanide dressing compared with a polyhexanide
swab (RR 1.48, 95% CI 1.02 to 2.13); patients in the dressing group also reported less pain (MD −2.03, 95% CI −2.66 to −1.40).
There was no clear evidence of a difference between interventions in infection resolution in three other comparisons. Evidence for
secondary outcomes varied from moderate to very low quality; where no GRADE assessment was possible we identified substantial
limitations which an assessment would have taken into account.
Authors’ conclusions
The relative effects of systemic and topical antimicrobial treatments on pressure ulcers are not clear. Where differences in wound
healing were found, these sometimes favoured the comparator treatment without antimicrobial properties. The trials are small, clinically
heterogenous, generally of short duration, and at high or unclear risk of bias. The quality of the evidence ranges from moderate to very
low; evidence on all comparisons was subject to some limitations.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics and antiseptics for pressure ulcers
What are pressure ulcers and who is at risk?
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are wounds involving the skin and often the tissue that
lies underneath. Pressure ulcers can be painful, may become infected, and affect people’s quality of life. People at risk of developing
pressure ulcers include those with spinal cord injuries, and those who are immobile or have limited mobility, such as elderly people and
people who are ill.
Why use antiseptics and antibiotics to treat pressure ulcers?
Where pressure ulcers are infected, antibiotics or antiseptics are used to kill or slow the growth of the micro-organisms causing the
infection and may prevent an infection from getting worse or spreading. This may also help the ulcer to heal. Where ulcers are not
infected they usually still have populations of micro-organisms present. It is thought that they may heal better if these are reduced by
antimicrobial agents. However, the relationship between infection and micro-organism populations in wounds and wound healing is
not very clear.
What we found
In October 2015 we searched for as many studies as we could find that were randomised controlled trials and compared the use of
an antibiotic or antiseptic with other treatments for pressure ulcers. We found 12 trials involving a total of 576 participants. Most
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study participants were older people in hospital. Most ulcers were not infected at the start of the trials. The different treatments
assessed included povidone iodine, cadexomer iodine, gentian violet, lysozyme, silver dressings, honey, pine resin, silver sulfadiazine,
polyhexanide and a combination of nitrofurazone and ethoxy-diaminoacridine. Silver sulfadiazine and nitrofurazone are topical (locally
acting) antibiotics while the other treatments are antiseptics. No trials looked at systemic (acting across the whole body) antibiotics.
The treatments were compared with each other or to treatments without antimicrobial qualities. Most evidence on wound healing
came from trials comparing antiseptics to treatments without antimicrobial qualities.
There was no consistent evidence of a benefit to using any particular antimicrobial treatment for pressure ulcers. However, there was
some limited evidence that more ulcers healed when treated with some types of alternative dressings without antimicrobial properties
than when treated with povidone iodine. All the studies had low numbers of participants, and in some cases these numbers were very
small. Many studies did not report important information about how they were carried out so it was difficult to tell whether the results
presented were likely to be true. More, better quality, research is needed to determine the effects of antimicrobial treatments on pressure
ulcers.
B A C K G R O U N D
Description of the condition
Pressure ulcers, also known as bedsores, decubitus ulcers, pres-
sure injuries or pressure sores are defined as “a localized injury
to the skin and/or underlying tissue usually over a bony promi-
nence, as a result of pressure, or pressure in combination with
shear” (EPUAP-NPUAP-PPPIA 2014). Pressure ulcers are a type
of complex wound that heals by secondary intention (through the
growth of new tissue).
Prolonged exposure of an area of the body to pressure or compres-
sion can damage cells, interrupt the local blood circulation (i.e.
reduce perfusion), and trigger a cascade of biochemical changes
that may lead to tissue damage and ulceration (Gebhardt 2002;
Loerakker 2010). Immobility can also lead to increased damage
from shear and friction, for example, when people are pulled into
position in chairs and beds.
People at particular risk of pressure ulcers are those who cannot
reposition themselves when they are seated in a chair or lying
in bed. This includes those with limited activity and mobility
or reduced bodily sensation, such as elderly people, people with
spinal cord injuries (Gefen 2014), and those with acute or chronic
health conditions (Allman1997; Bergstrom1998; Berlowitz 1990;
Brandeis 1994). A recent systematic review, Coleman 2013, iden-
tified the key risk factors for pressure ulcers as: limitations of mo-
bility or activity; reduced perfusion (including a diagnosis of di-
abetes); and the presence of a stage 1 pressure ulcer (see classi-
fication below). A recent cohort study found that predictors of
poor healing included the severity of the ulcer and the presence of
peripheral arterial disease (poor circulation/perfusion of the limb;
McGinnis 2014).
Children with pressure ulcers are recognised as a discrete popula-
tion that includes both neonates and older children with a range of
conditions and risk factors (EPUAP-NPUAP-PPPIA 2014; NICE
2014); they are cared for in specialist paediatric facilities, and, ac-
cordingly, are outside the scope of this review.
Classification of pressure ulcers
One of the most widely recognised ways of classifying pressure
ulcers according to severity is that of the National Pressure Ulcer
Advisory Panel (NPUAP). Their international classification recog-
nises four categories, or stages, of pressure ulcers and two cate-
gories of unclassifiable pressure injuries in which wound depth or
extent, or both, cannot be accurately determined: such ulcers are
generally severe and would be grouped clinically with category 3
or 4 ulcers (EPUAP-NPUAP-PPPIA 2014). The definitions for
the categories of severity for ulcers are as follows:
Category/Stage 1: non-blanchable erythema: “Intact skin with
non-blanchable redness of a localised area usually over a bony
prominence. Darkly pigmented skin may not have visible blanch-
ing; its colour may differ from the surrounding area. The area may
be painful, firm, soft, warmer or cooler as compared to adjacent
tissue. Category/Stage I may be difficult to detect in individuals
with dark skin tones.May indicate ’at risk’ individuals (a heralding
sign of risk).”
Category 2: partial thickness tissue loss: “Partial thickness loss of
dermis presenting as a shallow open ulcer with a red pink wound
bed, without slough. May also present as an intact or open/rup-
tured serum-filled or sero-sanguinous filled blister. Presents as a
shiny or dry shallow ulcer without slough or bruising (bruising
indicates suspected deep tissue injury). This category/stage should
not be used to describe skin tears, tape burns, perineal dermatitis,
maceration or excoriation.“
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Category 3: full thickness tissue loss: ”Full thickness tissue loss.
Subcutaneous fat may be visible but bone, tendon or muscle are
not exposed. Slough may be present but does not obscure the
depth of tissue loss.May include undermining and tunnelling. The
depth of a Category/Stage III pressure ulcer varies by anatomical
location. The bridge of the nose, ear, occiput and malleolus do
not have subcutaneous tissue and Category/Stage III ulcers can
be shallow. In contrast, areas of significant adiposity can develop
extremely deep Category/Stage III pressure ulcers. Bone/tendon
is not visible or directly palpable.“
Category 4: full thickness tissue loss with exposed muscle, ten-
don or bone: ”Full thickness tissue loss with exposed bone, ten-
don or muscle. Slough or eschar may be present in some parts of
the wound bed. Often includes undermining and tunnelling. The
depth of a Category/Stage IV pressure ulcer varies by anatomical
location. The bridge of the nose, ear, occiput and malleolus do
not have subcutaneous tissue and these ulcers can be shallow. Cat-
egory/Stage IV ulcers can extend into muscle and/or supporting
structures (e.g., fascia, tendonor joint capsule)making osteomyeli-
tis possible. Exposed bone/muscle is visible or directly palpable.“
The two additional categories of unclassifiable wounds that are
also recognised are:
Unstageable/unclassified: full thickness skin or tissue loss-
depth unknown: ”Full thickness tissue loss in which actual depth
of the ulcer is completely obscured by slough (yellow, tan, gray,
green or brown) and/or eschar (tan, brown or black) in the wound
bed. Further description: Until enough slough and/or eschar are
removed to expose the base of the wound, the true depth cannot
be determined; but it will be either a Category/Stage III or IV. Sta-
ble (dry, adherent, intact without erythema or fluctuance) eschar
on the heels serves as “the body’s natural (biological) cover” and
should not be removed.“
Suspected deep tissue injury - depth unknown: ”Purple or ma-
roon localized area of discoloured intact skin or blood-filled blis-
ter due to damage of underlying soft tissue from pressure and/
or shear. Further description: The area may be preceded by tissue
that is painful, firm, mushy, boggy, warmer or cooler as compared
to adjacent tissue. Deep tissue injury may be difficult to detect
in individuals with dark skin tones. Evolution may include a thin
blister over a dark wound bed. The wound may further evolve and
become covered by thin eschar. Evolution may be rapid exposing
additional layers of tissue even with treatment.“
Prevalence
Pressure ulcers are one of the most common types of complex
wound. Prevalence refers to the number of people with a pressure
ulcer at a point in time, or during a specific time period (Bonita
2006). Prevalence estimates differ according to the population as-
sessed, the assessment methods used and the category or categories
of ulcers that are included in the estimates.
In the UK, national pressure ulcer data are collected across com-
munity and acute settings - although data collection is not yet
universal - as part of the National Health Service (NHS) Safety
Thermometer initiative (Power 2012). In April 2014, prevalence
in NHS patients was 4.6% (NHS 2014). These data represent pa-
tients cared for across a range of settings including acute hospital
wards, community and residential care and at home.Most patients
had category 2 ulcers (3.0%), with 1.1% having category 3 and
0.6% having category 4 ulcers (category 1 ulcers were not included
in the reporting). The point prevalence of pressure ulceration in
the total adult population (rather than those currently receiving
medical treatment) was recently estimated using a cross-sectional
survey undertaken in Leeds, in theUK.The total adult population
was 751,485, and the point prevalence (including stage I ulcers)
was 0.31 per 1000 (Hall 2014). Pressure ulcer prevalence estimates
specifically for community settings have reported rates of 0.77 per
1000 adults in a UK urban area (Stevenson 2013).
Worldwide figures show a range of prevalence for pressure ulcers.
Data from theUSA showed that incidence of facility-acquired (i.e.
hospital-acquired) ulcers ranged from 9.2% (general cardiac care)
to 10.3% (surgical intensive care unit) of which 3.3% were se-
vere (category 3/4/unclassifiable; VanGilder 2009). Australian es-
timates of pressure ulcer prevalence in acute care range from 4.5%
to 27% (Prentice 2001), while in Japan prevalence across 5000
hospitals was reported as being 4.26% (Sanada 2008). Lower fig-
ures (1.8%) were noted in a cross-sectional descriptive study of
pressure ulcer prevalence in a teaching hospital in China (Zhao
2010), though data from a survey of hospital patients across sev-
eral European countries found an overall prevalence of 10.5%
(Vanderwee 2007). A review of pressure ulcer prevalence across
Scandinavia, Iceland and Ireland, found that the mean prevalence
in Norway was 17% (range 4.8% to 29%), 16% in Ireland (range
4% to 37%), 15% in Denmark (range 2.2% to 35.5%), 25%
in Sweden (range 0.04% to 42.7%), and 8.9% in Iceland (single
study, no range available) (Moore 2013a).
The prevalence in high-risk population groups may be very much
higher: a survey of people with a spinal cord injury found a point
prevalence of 23%; furthermore, the lifetime risk in this group is
estimated to be 70% (Raghaven 2003).
Cost of pressure ulcers
The cost of treating pressure ulcers in the UK has been estimated
to range from GBP 1214 for a category 1 ulcer to GBP 14,108
for a category 4 ulcer (Dealey 2012). These cost estimates may
be conservative due to the omission of negative pressure wound
therapy from costings, which were updated from a point prior
to the widespread use of this therapy; they also do not include
precautions required for dealingwith antibiotic-resistant infection.
The main driver of these increased costs is not ulcer category per
se but the increased rate of complications in higher category ulcers
and the subsequent increase in time to healing. In the UK, for the
year 2000, the total cost for treating pressure ulcers lay between
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GBP 1.4 billion and GBP 2.1 billion (Bennett 2004).
Pressure ulcers increase length of hospital stay and associated hos-
pital costs (Allman 1999). Figures from theUSA suggest that ’pres-
sure ulcer’ was noted as a diagnosis for half a million hospital
stays in 2006; for adults, the total hospital cost for these stays was
USD 11 billion (Russo 2008). Current data on costs from other
healthcare systems are hard to identify, but costs to the Australian
healthcare system for treating pressure ulceration have been esti-
mated at AUD285million annually (Graves 2005). There is also a
substantial societal non-health service cost in prolonged sick leave
(absence due to being unwell) for people who are in employment
when they develop a pressure ulcer (Gorecki 2009).
Impact of pressure ulcers on people
The impact of pressure ulcers on affected individuals is large. A
systematic review found that pressure ulcers had an impact across
physical, social and psychological domains as a result of one or
more of the following distressing symptoms: pain, exudate and
odour, increased care burden, prolonged rehabilitation, require-
ment for bed-rest, and hospitalisation (Gorecki 2009). The ad-
justed health-related quality of life of people with pressure ulcers
has been shown to be lower than that for comparable individu-
als without pressure ulcers (Essex 2009). Pressure ulcers may also
become infected, and this can give rise to serious systemic (whole
body) infections.
Wound infection
Complex wounds such as pressure ulcers offer an ideal environ-
ment for microbial colonisation: this is especially true for those
pressure ulcers that may be particularly exposed to bacterial con-
tamination from faecal material (Bowler 2001). However, most
wounds will contain some micro-organisms and this will not nec-
essarily lead to adverse events (WUWHS 2008).
There are several recognised definitions for wound infection (e.g.
CDC 2008; WUWHS 2008). Recently there has been a move
away from the view that density of bacteria is the key factor (i.e.
that a bacterial load greater than 1 x 105 g−1 is a predictor of in-
fection) towards the view that infection with enough - or specific
types of - pathogenic micro-organisms, or both (Bowler 2003;
Davies 2007; Madsen 1996; Trengove 1996), and the possible
production of biofilms (Percival 2004; Wolcott 2008), may lead
to negative outcomes and potentially delay healing. However, the
impact of microbial colonisation on wound healing is not inde-
pendent of the host response; the ability of the host to provide
an adequate immune response is likely to be as critical in deter-
mining whether a wound heals as the specifics of the flora in the
wound. Regarding wound flora, investigation into the microbiol-
ogy of pressure ulcers has been limited - one study of the bacteria
present in 25 pressure ulcers of different categories found a mean
number of 5.8 species when necrotic tissue was present, but only
1.7 species when it was not (Sapico 1986). A more recent prospec-
tive cohort study followed 145 patients with category 2 or higher
pressure ulcers: 77%of these people had pressure ulcers containing
Staphylococcus aureus, Gram-negative bacilli or both (Braga 2013).
The document ’Wound Infection in Clinical Practice - An Inter-
national Consensus’ defines a scenario leading to wound infection
where ”bacteria multiply, healing is disrupted and wound tissues
are damaged (local infection)“ (WUWHS 2008). The document
also notes that”Bacteria may produce problems nearby (spreading
infection) or cause systemic illness (systemic infection)“. Indeed,
wound infection has been conceptualised as being at one end of a
continuum of infection (Kingsley 2004).
Kingsley defined a continuumof infection that beginswith sterility
(a brief period, possibly following surgery) and progresses through
contamination (presence of microbes but little active growth and
no clinical problems), to colonisation (the normal status quo with
wound flora being managed by the host immune system and no
damage to wound tissues), culminating in critical colonisation and
then infection (Kingsley 2004).
In addition, Kingsley defined critical colonisation as a point be-
tween colonisation and infection where the ’healthy’ balance of
wound flora is no longer maintained by the host, and the bacterial
load or species present in the wound, or both, shift away from a
so-called safe level (Kingsley 2004). Others have conceptualised
critical colonisation as invasion of the wound surface by micro-
organisms (AWMA 2011; Edwards 2004).
The classic clinical signs of infection include localised pain, heat,
redness, swelling and purulence (pus). The concept of critical
colonisation lacks clear diagnostic criteria; it is generally noted
as being associated with delayed healing in the absence of overt
signs of wound infection (Carville 2008; Cutting 2004), possibly
with other symptoms such as increased exudate (though less than
in infection) and hypergranulation/friable tissue (Cutting 2004;
Gardner 2001), although associated evidence is limited.
We have been unable to identify recent or large-scale data on the
rates of clinical infection of pressure ulcers; early studies of small
numbers of patients produced an estimate of 1.4 cases of infection
per 1000 patient days with an ulcer (Nicolle 1994), while a point
prevalence study found that 6% of all nursing home residents
participating received treatment for an infected pressure ulcer (
Garibaldi 1981).
Although there is a widespread view amongst those with clinical
expertise in the field that healing of pressure ulcers is likely to be
retarded by critical colonisation or topical/local infection, the em-
pirical evidence to support this is extremely limited (Howell-Jones
2005). Indeed, the Australian Wound Management Association
states that ”The true extent of bacterial impairment of wound heal-
ing is unknown“ (AWMA 2011). In particular there is a dearth
of clinical studies to demonstrate a link between infection resolu-
tion or reduction of the microbiological load and wound healing;
to date, randomised evidence has not supported a link between
reduction in bacterial load and faster healing in pressure ulcers
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(Jull 2013; O’Meara 2001; Storm-Versloot 2010). This may stem
in part from the difficulty of culturing micro-organisms from the
biofilms present in pressure ulcers (Smith 2010), meaning that
microbiological load is not accurately represented in samples.
There is a limited and conflicting evidence base for the relation-
ship between bacterial load, or diversity or structure, and wound
healing in other types of chronic wounds such as venous leg and
diabetic foot ulcers (Davies 2007; Halbert 1992; Hansson 1995;
Madsen 1996;Moore 2010; Sotto 2012). The applicability of this
evidence to pressure ulcers is uncertain, as there are known micro-
biological differences between the wound types. In particular the
proportion of anaerobic bacteria (thought to be correlated with
non-healing) and mycobacteria appears to be higher in pressure
ulcers than in venous leg ulcers (Dowd 2008). There are known
differences in themicrobiology of pressure ulcers at different stages
of healing, but no demonstration that these differences are impli-
cated in the healing process (Sapico 1986).
Description of the intervention
Standard care for adults with pressure ulcers includes the use of
pressure redistribution devices such as high-specification foam
mattresses or cushions, or both (McInnes 2011); debridement
where appropriate and non-gauze dressings (BNF 2013), with
foam, hydrocolloid or alginate bases (NICE 2014). Other gen-
eral strategies include the provision of patient education, manage-
ment of pain, optimising circulation/perfusion, optimising nu-
trition and, where appropriate, performing surgical wound clo-
sure (AWMA2011; EPUAP-NPUAP-PPPIA 2014). Treatment of
clinical infection is also a key strategy as it is thought that a locally
infected wound might show retarded healing and may give rise to
a systemic infection.
Routine use of antibiotics and antiseptics is not currently recom-
mended for the treatment of uninfected pressure ulcers in adults,
and systemic antibiotics are recommended only when there is clin-
ical evidence of systemic sepsis (serious infection), spreading cel-
lulitis (deep skin infection) or underlying osteomyelitis (bone in-
fection; NICE 2014). Antibiotic use should be restricted to cases
of clear clinical need in the treatment of pressure ulcers, as with all
conditions. Internationally, antibiotic-resistant bacteria and mul-
tidrug-resistant bacteria are increasing as a clinical problem; these
bacteria have been found in isolates from a substantial propor-
tion of patients with pressure ulcers, even in community settings
(Cataldo 2011; Ellis 2003; Heym 2004). Inappropriate use of an-
tibiotics is not restricted to those given systemically; topical antibi-
otics are also not recommended for use on non-infected wounds
(NICE 2014).
There are two main approaches when an antimicrobial interven-
tion is considered clinically appropriate: an antibiotic may be ad-
ministered systemically (orally, intravenously or intramuscularly),
or a topical antibiotic or antiseptic may be applied (NICE 2014).
Antibiotics are substances that destroy or inhibit the growth of
micro-organisms (Macpherson 2004). Systemic antibiotic treat-
ments include groups of drugs that share similar modes of action
such as penicillins, cephalosporins, aminoglycosides, macrolides
and quinolones. Other antibiotics that do not belong to one of
these main groups include clindamycin, metronidazole, trimetho-
prim and co-trimazole (BNF 2013).
Topical antimicrobial agents that are applied directly to the ulcer
include both antibiotics and antiseptics. Antiseptics are thought
to prevent the growth of pathogenic micro-organisms without
damaging living tissue (Macpherson 2004). Topical applications
broadly fall into lotions used for wound irrigation or cleaning with
a brief contact time (unless used as a pack/soak placed into or onto
the wound), or both, and products that are in prolonged contact
with the wound such as creams, ointments and impregnated dress-
ings (BNF 2013). Agents used primarily for wound irrigation/
cleaning are commonly based on povidone-iodine, chlorhexidine
and peroxide agents. Less commonly used agents include tradi-
tional products such as gentian violet and hypochlorites. Creams
and ointments for longer contact include fusidic acid, mupirocin,
neomycin sulphate and iodine (often as cadexomer iodine; BNF
2013).
The British National Formulary (BNF) categorises antimicro-
bial dressings under honey-based, iodine-based, silver-based and
’other’, which includes dressings impregnated with agents such
as chlorhexidine or peroxides. Recommendations about dressing
types for wounds thought to be infected are based primarily on the
level of wound exudate, as this determines the dressing substrate,
as well as the antimicrobial agent (BNF 2013).
Despite guidance from NICE there is a high use of silver dress-
ings (11%) compared with other antimicrobial dressings (2% for
next most commonly prescribed antimicrobial dressing) (MeReC
2010). High prescription costs mean that silver dressings account
for a disproportionate amount (22%) of the annual NHS expen-
diture on dressings (MeReC 2010). It seems possible that some
of these dressings are being used prophylactically (i.e. to prevent
infection in wounds that are not clinically infected). There is also a
high level of use of both systemic antibiotics and topical agents in
patients with chronic wounds. General practice morbidity data for
Wales from 2000 showed that twice as many patients with chronic
wounds were prescribed systemic antibiotics in the previous year
compared with matched controls, with a mean number of pre-
scriptions per year of 2.3 (range 0 to 22) compared with 0.6 (range
0 to 14) for control patients. The same data showed high levels
of prescription for topical agents such as silver sulfadiazine (185
times per 1000 patients per year) and metronidazole (223 times
per 1000 patients per year) in this group (Howell-Jones 2006).
Again it appears possible that some prescriptions may be for the
treatment of wounds that are not clinically infected.
How the intervention might work
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The rationale for treating clinically infected wounds with antimi-
crobial and antiseptic agents is to kill or slow the growth of the
pathogenic micro-organisms, thus preventing an infection from
worsening and spreading (Kingsley 2004). Improved healing may
be a secondary benefit, although evidence of an association be-
tween wound healing and infection is limited (see Description of
the intervention; Jull 2013;O’Meara 2001; Storm-Versloot 2010).
There is a widely held view that wounds that do not show clear
signs of clinical infection, but have characteristics such as retarded
healing, may also benefit from a reduction in bacterial load. Again,
evidence for this is limited (see Description of the condition;
AWMA 2011, Howell-Jones 2005).
Normally antibiotics work by inhibiting DNA or protein synthe-
sis, or by disrupting bacterial cell walls. Antiseptics can be bacte-
riocidal (in that they kill micro-organisms) or they can work by
slowing the growth of organisms (bacteriostatic). Antiseptics can
have a wide spectrum of action that is not restricted to bacteria,
and often work by damaging the surface of microbes (Macpherson
2004).
Why it is important to do this review
Whether systemic or topical antimicrobials or topical antiseptics
can promote healing in pressure ulcers remains uncertain. An ear-
lier systematic review of antimicrobial agents used for the treat-
ment of all types of chronic wounds was not able to generate
definitive conclusions about the use of systemic or topical agents in
pressure ulcers because of methodological problems in the primary
literature (O’Meara 2001). Since the first review was published,
a substantial number of additional relevant trials have been pub-
lished that relate to pressure ulcers; these include trials of silver-
or honey-based topical preparations. This review is one of a num-
ber of Cochrane reviews investigating the use of antibiotics and
antiseptics in the treatment of different types of complex wounds,
each of which updates elements of the original O’Meara review
(O’Meara 2001).While there will be some overlap with Cochrane
reviews of individual antimicrobial agents in wounds (Jull 2013;
Storm-Versloot 2010), and with reviews of different types of dress-
ings (Dumville 2015a; Dumville 2015b; Moore 2013b), this re-
view will provide a single synthesis of the randomised evidence re-
lating to all systemic and topical antimicrobials for pressure ulcers.
Two notable systematic reviews of a range of treatments for pres-
sure ulcers have included some types of antimicrobial treatments
in wider assessments of dressings or topical treatments (Reddy
2008; Smith 2013). A comprehensive review of all antiseptic and
antibiotic treatment of pressure ulcers is, however, lacking.
There is a wide range of options available to health professionals
who are considering using antimicrobial therapy for pressure ul-
cers, either as a treatment for or prophylaxis against clinical infec-
tion. Evidence-based decision-making on the impact of antimi-
crobial agents on healing of pressure ulcers can be challenging.
Key problems include decisions about whether or when to use an
antimicrobial agent instead of standard care, and whether different
anti-microbial preparations have different impacts on healing.
O B J E C T I V E S
To assess the effects of systemic and topical antibiotics, and topi-
cal antiseptics on the healing of infected and uninfected pressure
ulcers being treated in any clinical setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Elements of this Methods section are based on the standard
Cochrane Wounds Protocol Template.
We included published and unpublished randomised controlled
trials (RCTs), including cluster RCTs, irrespective of language of
report.We included cross-over trials only if they reported outcome
data at the end of the first treatment period, prior to cross-over.
Quasi-randomised studies were excluded. We included RCTs re-
ported only as abstracts only when available datawere sufficient for
reasonable data extraction either from the abstract itself or from
the study authors.
Types of participants
We included studies that recruited adults diagnosed with a pres-
sure ulcer of category 2 or above (i.e. worse) managed in any care
setting. We excluded participants with category 1 ulcers. We ac-
cepted study authors’ definitions of what they classed as a category
2 or above pressure ulcer unless it was clear that wounds with un-
broken skin were included. This included accepting authors’ deci-
sions that a wound was a pressure ulcer rather than, for example,
an incontinence related sore/wound. Studies that recruited par-
ticipants with category 2 or above pressure ulcers alongside peo-
ple with other types of wounds were included if the proportion
of participants with pressure ulcers of category 2 or above was at
least 75%. We did not restrict the review to trials that recruited
only participants with colonised, critically colonised or infected
wounds at baseline, but where information about wound status
is reported it was recorded. Unstageable ulcers were included and
recorded as such.
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Types of interventions
The primary interventions of interestwere topical antiseptic agents
or antibacterial (antibiotic) agents delivered either systemically or
topically. We included any RCT in which the use of a topical or
systemic antibiotic or a topical antiseptic was the key systematic
difference between treatment groups. Systemic antibiotics may be
administered orally or by other routes (e.g. intravenously, intra-
muscularly). Both intervention and control regimens could con-
sist of antibiotics or antiseptics administered singly or in combina-
tion; control regimens might also include placebo, another ther-
apy, standard care or no treatment. Studies that evaluated co-inter-
ventions (e.g. pressure-relieving devices) were included, provided
that these treatments were delivered in a standardised way across
the trial arms. We decided to include studies where dressings as
well as antiseptic or antibiotic treatment differed between groups
for this review.
We excluded evaluations of antibiotics/antiseptics used to prepare
for the surgical treatment of ulcers (i.e. the surgical closure of ulcers
or skin grafting), and physical and biological therapies sometimes
purported to have incidental antimicrobial properties such as heat
therapy and larval therapy.
We anticipated that interventions would consist of antiseptic and
antibiotic agents, which might include (but not be limited to)
the following topical agents that may be available in the form of
creams, sprays, ointment, or impregnated into different types of
dressings: chlorhexidine; povidone-iodine; hydrogen peroxide and
potassium permanganate; benzoyl peroxide; hypochlorites (e.g.
Eusol); gentian violet; mupirocin and fusidic acid; neomycin sul-
phate; peroxides; iodine, silver and honey.
Systemic antibiotics might include penicillins, cephalosporins,
aminoglycosides, macrolides and quinolones, clindamycin,
metronidazole, trimethoprim and co-trimazole.
Types of outcome measures
We list primary and secondary outcome measures below. If a trial
was otherwise eligible (correct study design, population and inter-
vention/comparator) but did not report a relevant listed outcome,
then we contacted the study authors where possible in order to
establish whether the outcome was measured but not reported.
We report outcomemeasures at the latest time point available for a
study (assumed to be length of follow-up if not specified) and the
time point specified in the methods as being of primary interest (if
this is different from latest time point available). For all outcomes
we classed (and categorised) outcomes from:
• one to eight weeks as short-term;
• between eight and 26 weeks as medium-term; and
• over 26 weeks as long-term.
Review authors used their judgement based on consideration of
heterogeneity to determinewhether statistical poolingwithin these
time categories was appropriate.
Primary outcomes
The primary effectiveness outcome for this review was wound
healing. Trialists used a range of different methods of measuring
and reporting this outcome. RCTs that reported one or more of
the following were considered to provide the most relevant and
rigorous measures of wound healing.
• Time to complete wound healing (correctly analysed using
survival, time-to-event approaches). Ideally the outcome will be
adjusted (by study authors) for appropriate covariates e.g.
baseline ulcer area/duration.
• Proportion of wounds completely healed during follow-up
(frequency of complete healing).
We used, and reported, authors’ definitions of complete wound
healing. We reported outcome measures at the latest time point
available (assumed to be length of follow-up, if not specified) and
the time point specified in themethods as being of primary interest
(if this was different from latest time point available).
Where both the outcomes above were reported we planned to
present all data for reference, but to focus on reporting time to
healing. When time was analysed as a continuous measure, but it
was unclear whether all wounds healed, we documented the use
of the outcome in the study, but did not extract, summarise or use
the data in a meta-analysis.
The primary safety outcome for the review was all reported ad-
verse events. Reported data were extracted on all serious and non-
serious adverse events when a clear methodology for the collec-
tion of adverse event data was provided. This methodology had
to make it clear whether events were reported at the participant
level or whether multiple events/person were reported, in which
case appropriate adjustments needed to be made for data cluster-
ing. Individual types of adverse events other than pain or infection
were not extracted (see Secondary outcomes).
Secondary outcomes
The following secondary outcomes were included.
• Change (and rate of change) in wound size, with
adjustment for baseline size (we attempted to contact study
authors to request adjusted means when not presented). When
change or rate of change in wound size was reported without
adjustment for baseline size, use of the outcome in the study was
documented, but data were not extracted, summarised or used in
any meta-analysis.
• Changes in infection status; signs or symptoms of clinical
infection (we used study authors’ definitions of clinical
infection). We did not include data on bacterial load, diversity or
the presence of individual species, where it was not clear how the
outcome related to infection.
• Changes in bacterial (antibiotic) resistance.
• Health-related quality of life: quality of life was included
when it was reported using a validated scale such as the SF-36
(Ware 1992) or EQ-5D (EuroQoL Group 1990) or a validated
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disease-specific questionnaire such as the Cardiff Wound Impact
Schedule (Price 2004). Ideally the reported data were adjusted by
the study authors for the baseline score. We did not include ad
hoc measures of quality of life that were unlikely to be validated
and would not be common to multiple trials.
• Mean pain scores (including pain at dressing change) were
included only when reported as either a presence or absence of
pain, or as a continuous outcome using a validated scale such as a
visual analogue scale (VAS).
• Resource use (when presented as mean values with standard
deviation) including measures such as number of dressing
changes, number of nurse visits, length of hospital stay, need for
other interventions.
• Costs associated with resource use (including estimates of
cost-effectiveness).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of relevant clinical trials:
• The Cochrane Wounds Specialised Register (searched 20
October 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) (2015, Issue 9);
• Ovid MEDLINE (1946 to 20 October 2015);Ovid
MEDLINE (In-Process & Other Non-Indexed Citations)
(searched 20 October 2015);
• Ovid EMBASE (1974 to 20 October 2015);
• EBSCO CINAHL Plus (1937 to 20 October 2015).
The search strategies for CENTRAL, Ovid MEDLINE, Ovid
EMBASE and EBSCOCINAHL can be found in Appendix 1.We
combined the Ovid MEDLINE search with the Cochrane Highly
Sensitive Search Strategy for identifying randomised trials in
MEDLINE: sensitivity- and precision-maximising version (2008
revision) (Lefebvre 2011).We combined the EMBASE searchwith
the Ovid EMBASE filter developed by the UK Cochrane Centre
(Lefebvre 2011). We combined the CINAHL searches with the
trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2015). There were no restrictions with respect to
language, date of publication or study setting.
We also searched the following clinical trials registries:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch/
Default.aspx);
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/ctr-search/search).
Searching other resources
We attempted to identify other potentially eligible trials or ancil-
lary publications by searching the reference lists of retrieved in-
cluded trials, as well as relevant systematic reviews, meta-analyses
and health technology assessment reports.
Data collection and analysis
Selection of studies
Two review authors independently assessed the titles and abstracts
of the citations retrieved by the searches for relevance. After this
initial assessment, we obtained full text copies of all studies con-
sidered to be potentially relevant. Two review authors indepen-
dently checked the full papers for eligibility; disagreements were
resolved by discussion and, where required, through the input of
a third review author. When the eligibility of a study was unclear
we attempted to contact the study authors. We recorded all rea-
sons for exclusion of studies for which we obtained full copies of
the text. We completed a PRISMA flowchart to summarise this
process (Liberati 2009) (Figure 1).
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Figure 1. PRISMA study flow diagram.
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When studies were reported in multiple publications/reports, we
obtained all publications. Whilst the study was included only once
in the review, we extracted data from all reports to ensure all avail-
able relevant data were obtained.
Data extraction and management
We extracted and summarised details of the eligible studies. Where
possible we extracted data by treatment group for the pre-specified
interventions and outcomes in this review. Data were extracted by
one review author and checked by a second review author. Dis-
crepancies were resolved through discussion or by consultation
with a third review author. When data were missing from reports,
we attempted to contact the study authors to request this infor-
mation.
When a studywithmore than two intervention armswas included,
only data from the intervention and control groups that met the
eligibility criteria were extracted. When the reported baseline data
related to all participants rather than to those in relevant treatment
arms, the data for the whole trial were extracted and this was noted.
Outcome data were collected for relevant time points as described
in Types of outcome measures.
Where possible we extracted the following data:
• bibliographic data including date of completion/
publication;
• country of origin;
• unit of randomisation (participant/ulcer);
• unit of analysis;
• trial design, e.g. parallel; cluster;
• care setting;
• number of participants randomised to each trial arm and
number included in final analysis;
• eligibility criteria and key baseline participant data
including category or categories and location(s) of pressure
ulcers;
• details of treatment regimen received by each group;
• duration of treatment;
• details of any co-interventions;
• primary and secondary outcome(s) (with definitions and,
where applicable, time-points);
• outcome data for primary and secondary outcomes (by
group);
• duration of follow-up;
• number of withdrawals (by group) and number of
withdrawals (by group) due to adverse events;
• publication status of study;
• source of funding for trial.
Assessment of risk of bias in included studies
Two review authors independently assessed included studies using
the Cochrane tool for assessing risk of bias (Higgins 2011a). This
tool addresses six specific domains: sequence generation; alloca-
tion concealment; blinding; incomplete data; selective outcome
reporting; and other issues - in this review we recorded unit of
analysis issues, for example where a cluster trial has been under-
taken but analysed at the individual level in the study report. We
assessed blinding of outcome assessment and completeness of out-
come data for each of the review outcomes separately. We present
our assessment of risk of bias using two ’Risk of bias’ summary
figures; one is a summary of bias for each item across all stud-
ies, and a second shows a cross-tabulation of each trial by all of
the ’Risk of bias’ items. We summarised a study’s risk of selection
bias, detection bias, attrition bias, reporting bias and other bias. In
many of the comparisons included in this review we anticipated
that blinding of participants and personnel would not be possible.
For this reason, the assessment of the risk of detection bias focused
on whether blinded outcome assessment was reported. For trials
using cluster randomisation, we also planned to consider the risk
of bias in relation to: recruitment bias; baseline imbalance; loss
of clusters; incorrect analysis; and comparability with individually
randomised trials (Higgins 2011b) (Appendix 2).
Measures of treatment effect
Time-to-event data (e.g. time to complete wound healing) were
reported as hazard ratios (HRs) when possible, in accordance with
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011). If studies reporting time-to-
event data (e.g. time to healing) did not report a hazard ratio, then,
where feasible, we planned to estimate this using other reported
outcomes, such as numbers of events, through the application of
available statistical methods (Parmar 1998; Tierney 2007). For
dichotomous outcomeswe calculated the risk ratio (RR)with 95%
confidence intervals (CIs). For continuous outcome data, we used
the mean difference (MD) with 95% CIs for trials that used the
same assessment scale and, when trials used different assessment
scales, we planned to use the standardised mean difference (SMD)
with 95% CIs.
Unit of analysis issues
Where studies randomised at the participant level and measured
outcomes at the wound level, for example for wound healing, and
the number of wounds appeared to be equal to the number of
participants, we treated the participant as the unit of analysis.
We had anticipated a possible unit of analysis issue if individual
participants with multiple wounds were randomised. The allo-
cated treatment used on the multiple wounds per participant (or
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perhaps only on some participants) and then data were presented
and analysed by wound not person. This is a type of clustered data
and presents a unit of analysis error which inflates precision. In
cases where included studies contained some or all clustered data
we reported this alongside whether data had been (incorrectly)
treated as independent. We recorded this as part of the risk of bias
assessment. We did not undertake further calculation to adjust for
clustering.
Dealing with missing data
It is common to have data missing from trial reports. The exclu-
sion of participants from the analysis post randomisation or ignor-
ing those lost to follow-up compromises the randomisation and
potentially introduces bias into the trial. If we thought that study
authors might be able to provide some missing data, we contacted
them; however, data were often likely to be missing because of
loss to follow-up. In individual studies, when data were presented
for the proportion of ulcers healed, we assumed that randomly
assigned participants who were not included in the analysis had
an unhealed wound at the end of the follow-up period (i.e. they
were considered in the denominator but not in the numerator).
When a trial did not specify participant group numbers before
dropout, we present only complete case data. For time-to-healing
analysis using survival analysis methods, we planned to account
for dropouts as censored data. Hence, all participants would con-
tribute to the analysis. We acknowledge that such analysis assumes
that dropouts are missing at random and that there is no pattern
of missingness. We presented data for area change of ulcer and for
all secondary outcomes as complete case analyses.
We presented available data from the study reports/study authors
for continuous variables - for example length of hospital stay -
and for all secondary outcomes, and did not plan to impute miss-
ing data. Where measures of variance were missing we planned
to calculate these wherever possible (Higgins 2011a); where this
was not possible we attempted to contact study authors. When
these measures of variation remained unavailable and could not
be calculated, we planned to exclude the study from any relevant
meta-analyses.
Assessment of heterogeneity
Assessment of heterogeneity is a complex, multi-faceted process.
Firstly, we considered clinical and methodological heterogeneity,
that is the degree to which the included studies varied in terms
of participant, intervention, outcome and characteristics such as
length of follow-up. We planned to supplement this assessment
of clinical and methodological heterogeneity with information re-
garding statistical heterogeneity - we intended to assess this using
the Chi² test (P values less than 0.10 would have been considered
to indicate statistically significant heterogeneity) in conjunction
with the I² statistic (Higgins 2003). I² examines the percentage of
total variation across RCTs that is due to heterogeneity rather than
chance (Higgins 2003). Very broadly we intended to consider that
I² values of 25%, or less, may mean a low level of heterogeneity
(Higgins 2003), and values of 75% or more indicate very high
heterogeneity (Deeks 2011). Where there was evidence of high
heterogeneity we planned to attempt to explore this further: see
Data synthesis.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. Publication
bias is one of a number of possible causes of ’small study effects’,
that is, a tendency for estimates of the intervention effect to be
more beneficial in smaller RCTs. Funnel plots allow a visual as-
sessment of whether small study effects may be present in a meta-
analysis. A funnel plot is a simple scatter plot of the intervention
effect estimates from individual RCTs against some measure of
each trial’s size or precision (Sterne 2011). Funnel plots are only
informative when there are a substantial number of studies in-
cluded in an analysis; we planned to present funnel plots for meta-
analyses that included at least 10 RCTs using RevMan 2014 5.
Data synthesis
We combined details of included studies in a narrative review ac-
cording to the comparison between intervention and compara-
tor, the population and the time point of the outcome measure-
ment. We considered clinical and methodological heterogeneity
and planned to undertake pooling if studies appeared appropri-
ately similar in terms of ulcer category, intervention type and an-
timicrobial agent, duration of treatment and outcome assessment.
In terms of our meta-analytical approach, in the presence of clin-
ical heterogeneity (review author judgement) or evidence of sta-
tistical heterogeneity, or both, we planned to use the random-ef-
fects model. We planned only to use a fixed-effect approach when
clinical heterogeneity was thought to be minimal and statistical
heterogeneity was estimated as non-statistically significant for the
Chi² test and 0% for the I² statistic (Kontopantelis 2013). We
planned to adopt this approach as it is recognised that statisti-
cal assessments can miss potentially important between-study het-
erogeneity in small samples, hence the preference for the more
conservative random-effects model (Kontopantelis 2012). Where
clinical heterogeneity was thought to be acceptable or of interest
we planned to make a decision as to whether to meta-analyse even
when statistical heterogeneity was high but to attempt to inter-
pret the causes behind this heterogeneity and to consider using
meta-regression for that purpose, if possible (Thompson 1999;
Thompson 2002).
We presented data using forest plots where possible. For dichoto-
mous outcomes we presented the summary estimate as a risk ratio
(RR) with 95% CI. Where continuous outcomes were measured
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in the same way across studies we planned to present a pooled
mean difference (MD)with 95%CI; we planned to pool standard-
ised mean difference (SMD) estimates where studies measured the
same outcome using different methods. For time-to-event data,
we planned to plot (and, if appropriate, pool) estimates of hazard
ratios and 95% CIs as presented in the study reports using the
generic inverse variance method in RevMan 2014 5. Where time
to healing was analysed as a continuous measure but it was not
clear if all wounds healed, use of the outcome in the study was
documented, but those data were not summarised and we did not
plan to use the data in any meta-analysis.
’Summary of findings’ tables
We planned to present the main results of the review in ’Summary
of findings’ tables. These tables present key information concern-
ing the quality of the evidence, the magnitude of the effects of
the interventions examined, and the sum of available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of themain outcomes using theGRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) approach.
The GRADE approach defines the quality of a body of evidence as
the extent to which one can be confident that an estimate of effect
or association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schünemann 2011b). We planned to present the following
outcomes in the ’Summary of findings’ tables:
• Time to complete ulcer healing when analysed using
appropriate survival analysis methods;
• Proportion of ulcers completely healing during the trial
period;
• Changes in clinical infection status;
• Adverse events.
Because in each case only a single study evaluated a comparison we
did not present a full ’Summary of findings’ table but instead pro-
vide a narrative summary of the results of the GRADE assessment.
Where it was not possible to calculate an estimate of effect for an
outcome (including where this was due to zero events reported)
we did not provide a GRADE assessment; where this was the case
for all the outcomes for a comparison we did not provide GRADE
assessments but gave a single summary of the issues which would
have been taken into account in assessments.
Subgroup analysis and investigation of heterogeneity
When possible, we planned to perform subgroup analyses to ex-
plore the influence of ulcer category on effect size. If there were
sufficient data these analyses would have assessed whether there
were differences in effect sizes for category 2 pressure ulcers and
the more severe category 3 and 4 (and unclassifiable) pressure ul-
cers.
When possible, we planned to perform subgroup analyses to ex-
plore the influence of risk of bias on effect size. These analyses
would have assessed the influence of removing studies classed as
having high and unclear risk of bias from themeta-analyses. These
analyses would have included only studies that were assessed as
having low risk of bias in all key domains, namely, adequate gen-
eration of the randomisation sequence, adequate allocation con-
cealment and blinding of outcome assessor for the estimates of
treatment effect.
R E S U L T S
Description of studies
See Included studies; Excluded studies
Results of the search
The search generated 261 records. Reference checking of reviews
and included studies identified a further seven records. Twelve
studies reported in 18 publications were included in the review
(Figure 1). Ten studies were published in English, two were pub-
lished in Japanese (Imamura 1989; Toba 1997). Two studies
are pending classification once translation has occurred (Bigolari
1991; Goldmeier 1997); these were reported in Italian and Por-
tuguese respectively. We are not aware of any relevant ongoing
studies.
Included studies
This review includes 12 studies which together contained 576
randomised participants (Barrois 1993; Chuangsuwanich 2011;
Chuangsuwanich 2013; Imamura 1989; Kaya 2005; Kucan 1981;
Moberg 1983; Nisi 2005; Sipponen 2008; Toba 1997;Wild 2012;
Yapucu Güne 2007). Eleven studies had two arms, one (Kucan
1981) had three arms. Four studies involved multiple ulcers being
treated on some or all participants (Chuangsuwanich 2013; Kaya
2005; Moberg 1983; Sipponen 2008); all of these carried out
randomisation at the participant level and did not make it clear
whether the analysis was adjusted to reflect the clustered data from
some participants.
Interventions assessed
All the included studies assess the use of topical agents; there were
no eligible studies of systemic antibiotics. Most of the interven-
tions assessed were antiseptics.
There were four types of comparisons assessed:
1. Antiseptic versus non-antimicrobial intervention
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2. Antiseptic versus alternative antiseptic
3. Antiseptic versus antibiotic
4. Antibiotic versus non-antimicrobial intervention.
No trials compared different antibiotics with each other.
The largest amount of data available related to comparison of
antiseptics compared with non anti-microbial interventions. The
most commonly evaluated agent was povidone iodine which was
evaluated by four trials (Barrois 1993; Kaya 2005; Kucan 1981;
Nisi 2005). All these trials employed a different non-antimicro-
bial comparator and in one trial the iodine was combined with
sugar. Comparator treatments (without antimicrobial properties)
to which the interventions were compared included hydrogel
(Kaya 2005), hydrocolloid (Barrois 1993), protease-modulating
matrix (Nisi 2005), saline gauze (Kucan 1981), and standard care
(Moberg 1983). Single trials compared cadexomer iodine to stan-
dard care (Moberg 1983); and pine resin to hydrocolloid dressing
(Sipponen 2008).
For comparison 2 one trial compared povidone iodine sugar to
gentian violet (Toba 1997); one compared povidone iodine sugar
to lysozyme ointment (Imamura 1989); and one compared two
different formulations of polyhexanide (Wild 2012).
For comparison 3 two trials compared silver to silver sulfadi-
azine (silver mesh, Chuangsuwanich 2011; and silver alginate,
Chuangsuwanich 2013). One trial compared povidone iodine to
silver sulfadiazine (Kucan 1981). A fourth trial compared honey to
ethoxy-diaminoacridine administered with nitrofurazone (Yapucu
Güne 2007).
For comparison 4 a single trial compared silver sulfadiazine to
saline (Kucan 1981).
No individual comparison was evaluated by more than one trial
so all were considered separately; they are grouped by comparison
type.
Outcomes reported
Seven studies reported the primary effectiveness outcome of this
review: wound healing (Barrois 1993, Imamura 1989; Kaya 2005;
Moberg 1983; Nisi 2005; Sipponen 2008;Yapucu Güne 2007).
In all cases this was reported as proportion of wounds healed. No
trials appropriately reported time-to-healing data.
The primary safety outcome of the review was adverse ef-
fects. This was reported for all participants by six trials (Barrois
1993; Chuangsuwanich 2011; Imamura 1989; Moberg 1983;
Toba 1997; YapucuGüne 2007), four of which reported that there
were no adverse events. Individual events which would normally
be considered as adverse events were reported in some of the trials
reporting that no adverse events occurred, as well as by other trials
which did not report data for all participants.
The review evaluated a number of secondary outcomes. Six stud-
ies reported change in wound size data (Chuangsuwanich 2011;
Chuangsuwanich 2013; Imamura 1989; Moberg 1983; Toba
1997; Yapucu Güne 2007). Infection eradication data were re-
ported in five studies (Imamura 1989; Kucan 1981; Sipponen
2008; Toba 1997; Wild 2012); three enrolled only participants
with infected pressure ulcers at baseline. In Toba 1997 and Wild
2012 this related specifically to the presence of MRSA, which all
ulcers were positive for at baseline, and therefore to changes in
microbiological status. All other studies either did not report this
outcome or reported only qualitative data relating to species of
microorganisms present. No studies reported incidence of new in-
fections. Only two studies reported on pain (Moberg 1983; Wild
2012); and two studies reported some data on resource use (Barrois
1993; Nisi 2005). Costs related to resource use were reported by
Chuangsuwanich 2011 and Chuangsuwanich 2013. No trials re-
ported data on health-related quality of life.
Outcome data are summarised in Table 1.
Characteristics of participants
Most trials enrolled participants whowere elderly and hospitalised.
All the trials appeared to be conducted in secondary care settings.
Two did not report whether participants were hospitalised (Barrois
1993; Yapucu Güne 2007); one reported enrolling only outpa-
tients (Chuangsuwanich 2011); and two both inpatients and out-
patients (Chuangsuwanich 2013, Wild 2012). All other trials en-
rolled only hospital inpatients.
One trial enrolled participants with spinal cord injuries (Kaya
2005). Participants in this trial were much younger than those
in other studies, with a mean age of 32.8 years. Apart from Nisi
2005 (mean age 45 years) all other studies where it was reported,
had mean ages over 60 years and in some cases over 80 years. One
trial did not report age (Barrois 1993) while another reported an
age range of 16 to 102 years (Kucan 1981). Five trials did not
report the age of participants. There was variation in the stage of
ulcers present in included participants with two trials reporting a
minority of participants with stage I ulcers (Imamura 1989; Kaya
2005).
There was heterogeneity between the trials in terms of infection
at baseline. One trial specifically excluded participants with in-
fected or necrotic ulcers (Chuangsuwanich 2013); and one stated
that both infected and uninfected ulcers were eligible (Sipponen
2008). Barrois 1993 included only participants with necrotic ul-
cers but did not report whether these were infected while Kaya
2005 reported that none of the ulcers were infected. Three trials
only enrolled participants with infected ulcers (Kucan 1981; Toba
1997; Wild 2012) and two of these specified that MRSA must be
present (Toba 1997; Wild 2012); in one trial this was required to
be intractable (Wild 2012). The primary outcomes of these three
studies related to infection resolution. The other studies did not
specify whether ulcers were infected at baseline.
Sample sizes
The included trials had small sample sizes. The total number of
participants was 578 and the median sample size was 34 (range
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19 to 141); all except three studies (Barrois 1993; Imamura 1989;
Nisi 2005) had fewer than 50 participants; all of these assessed
povidone iodine.
Trial duration
The duration of the trials was generally short. All except two trials
which reported a clearly specified length had treatment durations/
outcome assessments which would be considered to be short term
according to the prespecified criteria used in this review, ranging
from 14 days to 8 weeks; reported follow-up ranged from 17 days
to six months. Two trials did not explicitly report durations which
were then inferred from the time-to-healing data reported (Kaya
2005; Nisi 2005); in Nisi 2005 the reported treatment durations
in the randomised phase ranged from 2 to 8 weeks with follow-
up at 8 weeks; while in Kaya 2005 treatment durations ranged
from 15 up to 106 days with most data from the lower end of this
range. These trials could therefore both be reasonably considered
to be reporting short-term outcome data. Toba 1997 reported
treatment duration of 14 weeks; follow-up was reported to be 2
years but data were reported for 14 weeks; outcomes in this trial
are therefore considered to be medium-term. The single trial with
a specified longer-term treatment duration and follow-up lasted
for six months (Sipponen 2008).
Excluded studies
Forty-six studies were excluded because they were not RCTs, did
not have at least 75% of participants with pressure ulcers, did not
report relevant outcomes or did not assess at least one antiseptic/
antibiotic intervention (Characteristics of excluded studies).
Risk of bias in included studies
All studies were assessed for risk of bias. Barrois 1993 could not be
fully assessed because it was reported in abstract form only; on the
basis of the abstract it was considered to be at unclear risk of bias
across all domains except for attrition bias where it was assessed as
being at low risk of bias. Results of the assessment are shown in
Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation sequence
Six studies were classed as being at low risk of bias for ran-
domisation (Chuangsuwanich 2011; Imamura 1989;Kucan 1981;
Sipponen 2008;Toba 1997;Wild 2012). Four trials reported using
a computer-generated randomisation sequence and two a table of
random numbers (Imamura 1989; Toba 1997). The remainder of
the studies were at unclear risk of bias.
Allocation concealment
Only one of the included trials clearly reported adequate alloca-
tion concealment (Imamura 1989); in all other cases it was un-
clear whether appropriate allocation concealment had been un-
dertaken (where sealed envelopes were used it was unclear if they
were opaque).
Blinding
Blinded outcome assessment: three studieswere judged to be at low
risk of detection bias (Chuangsuwanich 2013; Kucan 1981; Wild
2012). Two trials were considered to be at high risk of detection
bias because of nonblinded outcome assessment (Imamura 1989;
Yapucu Güne 2007). All other studies had an unclear risk of bias.
Incomplete outcome data
Two studies were judged to be at high risk of attrition bias
(Moberg 1983; Sipponen 2008). In both studies a high propor-
tion of randomised participants were not included in the analy-
sis. Seven studies were at low risk of attrition bias (Barrois 1993;
Chuangsuwanich 2011; Chuangsuwanich 2013; Nisi 2005; Toba
1997; Wild 2012; Yapucu Güne 2007) and the remainder had an
unclear risk.
Selective reporting
Six studies were judged to be at low risk of reporting bias
(Chuangsuwanich 2013; Kucan 1981; Moberg 1983; Sipponen
2008; Wild 2012; Yapucu Güne 2007) and all other studies had
an unclear risk of selective outcome reporting.
Other potential sources of bias
Four studies were identified as having potential unit of analysis
issues as some of the randomised participants had more than one
wound and it seemed that data were presented at the wound level
rather than the participant level (Chuangsuwanich 2013; Kaya
2005; Moberg 1983; Sipponen 2008). They were therefore con-
sidered to be at high risk of bias. Four studies were classed as being
at unclear risk of other sources of bias due to poor reporting of
methods (Barrois 1993; Chuangsuwanich 2011; Imamura 1989;
Toba 1997); the remainder had a low risk.
Effects of interventions
1. Antiseptics compared with non anti-microbial
interventions (6 trials, 284 participants)
Four trials compared povidone iodine with another treatment
which did not contain an antiseptic or antibiotic component
(Barrois 1993; Kaya 2005; Kucan 1981; Nisi 2005). As each trial
used a different comparator, and as there was also heterogeneity in
the application of povidone iodine, they are presented separately.
One trial compared cadexomer iodine with standard care (Moberg
1983); and one trial compared pine resin with antiseptic proper-
ties to a hydrocolloid dressing (Sipponen 2008).
Comparison 1. Povidone iodine versus hydrocolloid (1 trial;
76 participants)
One trial compared a gauze containing povidone iodine with a
hydrocolloid dressing (Barrois 1993). This trial was published as
an abstract only. It randomised 76 participants with open necrotic
pressure ulcers (stage not specified) to treatment with paraffin
gauze dressing with povidone iodine or a hydrocolloid dressing for
56 days or until healing occurred.
Primary outcome: wound healing (proportion of wounds
completely healed)
Barrois 1993 reported that after 56 days, 9/38 (23.7%) ulcers
treated with povidone iodine healed versus 10/38 (26.3%) treated
with hydrocolloid. There was no clear evidence of a difference
in wound healing between groups: RR 0.90 (95% CI 0.41 to
1.96) (Analysis 1.1).GRADE assessment: low quality evidence,
downgraded twice due to imprecision for the outcome of wound
healing. A GRADE assessment of low quality evidence means
that further research is very likely to have an important impact
on our confidence in the estimate of effect and is likely to change
the estimate.
Primary outcome: adverse events
Barrois 1993 reported that no adverse events were observed but
also reported data for participants who dropped out of the trial due
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to deterioration in the pressure sore; these data were not further
analysed.
Secondary outcome: resource use (dressings per week)
Barrois 1993 reported that participants treated with povidone io-
dine required a mean of 5.07 dressings per participant per week,
compared with 2.43 for those treated with hydrocolloid. No mea-
sure of variance was reported and the data were not further anal-
ysed.
Comparison 2. Povidone iodine versus hydrogel (1 trial, 27
participants)
One trial compared povidone iodine with a hydrogel-type dressing
(Kaya 2005). Twenty-seven hospitalised participants with spinal
cord injury and pressure ulcers were randomised to povidone io-
dine gauze or hydrogel treatment for the duration of the hospi-
tal stay. Treatment duration was not further specified and neither
was the length of follow-up (reported treatment times for the two
groups ranged from 16 to 106 days for the povidone iodine group
and from 15 to 91 days for the hydrogel group). Most participants
hadmore thanone ulcer treated.Twelve participantswith 24ulcers
were randomised to povidone iodine gauze and 15 participants
with 25 ulcers to hydrogel. Most (N = 34) of the 49 ulcers were
stage II with a minority (N = 12) of stage I ulcers and a smaller
number of stage III ulcers (N = 3). Stage II and III ulcers made
up 75.5% of all the ulcers evaluated. We therefore report results
for all ulcers.
Primary outcome: wound healing (proportion of wounds
completely healed)
Kaya 2005 reported that 13/24 (54.2%) ulcers treated with povi-
done iodine healed versus 21/25 (84%) treated with hydrogel.
The RR for wound healing after was 0.64 (95% CI 0.43 to 0.97)
in favour of hydrogel (Analysis 2.1). Numbers of stage II/III ul-
cers healed were also reported. The trial also reported mean time
to healing data but this was not extracted or analysed as not all
ulcers healed. GRADE assessment: low quality evidence due to
imprecision for the outcome of wound healing; (downgraded
once for imprecision due to the wide confidence intervals and
once because participants had multiple ulcers and it was not
clear whether the analysis was adjusted for the clustered data;
precision estimates are likely to change upon correct analysis of
data for the outcome).
Primary outcome: adverse events
Kaya 2005 did not report adverse events.
No review-relevant secondary outcomes were reported
Comparison 3. Povidone iodine versus saline (1 trial, 45
participants)
One three-arm trial compared povidone iodine with saline (Kucan
1981). Forty-five hospitalised participants with infected pressure
ulcers were randomised to povidone iodine gauze, saline gauze or
silver sulfadiazine (see comparison 5 and 11). Participants were
treated for three weeks or until the wound was considered clean
and ready for closure or the treatment was considered a failure.
All wounds were assessed at three weeks (duration of follow-up).
Debridement of necrotic tissue was carried out as required and
systemic antibiotics were prescribed for intercurrent infections;
their use was reported for 15 participants who were reported to be
equally distributed across the three groups.
Primary outcome: wound healing
Kucan 1981 did not report wound healing.
Primary outcome: adverse events
Kucan 1981 did not report adverse events.
Secondary outcome: infection eradication
Kucan 1981 defined infection eradication as a bacterial count of
less than 105/g after three weeks. The trial reported that after
three weeks 7/11 (63.6%) ulcers treatedwith povidone iodine were
judged to be free of infection compared with 11/14 (78.6%) ulcers
treated with saline. There was no clear evidence of a difference
between groups in eradication of infection: RR 0.81 (95%CI 0.48
to 1.37) (Analysis 3.1).GRADEassessment: low quality evidence
due to imprecision (downgraded twice for imprecision).
Comparison 4. Povidone iodine versus protease-modulating
matrix dressing (1 trial, 80 participants)
One trial compared povidone iodine with a protease-modulating
matrix dressing (Nisi 2005). Eighty hospital inpatients with pres-
sure ulcers of stages II to IV were randomised to daily disinfection
with 50% povidone iodine solution, saline washes and Vaseline
gauze, covered with a hydropolymer patch versus a protease-mod-
ulating matrix treatment (PROMOGRAN) changed two or three
times weekly, covered with a hydropolymer patch. This followed
a debridement phase for all participants which used surgical de-
bridement, disinfection with povidone iodine, saline washes and
use of hydrogels. Planned treatment duration was not reported
but actual duration of randomised treatment ranged from two to
eight weeks in the povidone iodine group and two to six weeks in
the protease-modulating group. Follow-up was for eight weeks.
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Primary outcome: wound healing (Proportion of wounds
completely healed)
In Nisi 2005 by eight weeks in the randomised groups 28/40
(70%) ulcers treated with povidone iodine had healed compared
with 36/40 (90%) treated with the protease-modulating dressing.
The RR for wound healing was 0.78 (95% CI 0.62 to 0.98) in
favour of protease-modulating dressings (Analysis 4.1). GRADE
assessment: moderate quality evidence, downgraded once due
to imprecision for the outcome of wound healing. A GRADE
assessment ofmoderate quality evidencemeans further research
is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate.
Primary outcome: adverse events
Nisi 2005 did not report adverse events
Secondary outcome: resource use (length of hospital stay)
Total length of hospital stay was reported as 1164 days in the povi-
done iodine group; 360 days in the protease-modulating group
(Nisi 2005). No measures of variance were reported and the data
are not further analysed.
Secondary outcome: resource use (dressing use)
The total number of dressing changes for the povidone iodine
group was reported as ranging from 14 to 52 and for the protease-
modulating group as ranging from six to 15 (Nisi 2005). Mean
number of dressings was not reported for either group and the
data were not further analysed.
Comparison 5. Cadexomer iodine versus standard care (1
trial, 38 participants)
One trial compared cadexomer iodine with standard care in 38
hospitalised participants (Moberg 1983). Participants were treated
and followed up for eight weeks. Stages of pressure ulcers were not
reported, rather they were classed as ”deep“ (N = 18) or ”super-
ficial“ (N = 16). Classification data were not reported for partici-
pants who withdrew early in the trial. Data for ulcer area change
were reported at both three and eight weeks.
Primary outcome: wound healing (proportion of wounds
completely healed):
In Moberg 1983 6/19 (31.6%) participants randomised to cadex-
omer iodine had ulcers completely healed at eight weeks versus
1/19 (5.3%) in the group treated with standard care. The RR
for complete wound healing was 6.00 (95% CI 0.80 to 45.20)
(Analysis 5.1). GRADE assessment: very low quality evidence
downgraded twice due to imprecision and once due to attrition
bias. A GRADE assessment of very low quality means that we
have very little confidence in the effect estimate: the true effect
is likely to be substantially different from the estimate of effect.
Primary outcome: adverse events
Moberg 1983 reported that there were no ”side effects“ in partici-
pants in the standard care group with data available for 13 partic-
ipants. 5/14 participants in the cadexomer iodine group reported
events that were considered as side effects. The RR for adverse
events was 10.27 (95%CI 0.62 to 169.16) (Analysis 5.2).GRADE
assessment: very low quality evidence downgraded twice for im-
precision and once for attrition bias.
Secondary outcome: change in wound size
Moberg 1983 reported change inwound area. Themean reduction
in wound area at 8 weeks was 76.2% (SE 8.2%) in the cadexomer
iodine group (data for 14 participants) compared with 57.4%
(SE 9.4%) in the standard care group (data for 13 participants).
The mean difference in wound area reduction was 18.80% (95%
CI −5.65 to 43.25) greater reduction in size in the cadexomer
iodine treated group (Analysis 5.3). GRADE assessment: very
low quality evidence downgraded twice due to imprecision and
once due to attrition bias.
Secondary outcome: pain
In Moberg 1983 pain was reported using a visual analogue scale
for 13 participants in each group. Pain score at baseline was 14.6
(SE 4.6) in the cadexomer iodine group and 13.3 (SE 5.6) in
the standard care group. Pain at 8 weeks was 3.1 (SE 1.7) in the
cadexomer iodine group and 7.5 (SE 2.8) in the standard care
group. The mean difference in pain score at 8 weeks was −4.40
(95% CI −10.82 to 2.02), (Analysis 5.4). GRADE assessment:
very low quality evidence downgraded twice due to imprecision
and once due to attrition bias.
Comparison 6. Pine resin salve versus hydrocolloid (1 trial,
37 participants)
One trial (Sipponen 2008) compared spruce resin salve 1 mm
thick between loose sterile cotton gauze changed every day with
either a hydrocolloid dressing without antiseptic agent or a silver
hydrocolloid dressing (where there was evidence of wound infec-
tion). The trial enrolled primary care hospital patients with stages
II-IV pressure ulcers. Several participants had more than one ul-
cer; 37 participants with 45 ulcers were randomised and it was not
clear whether the analysis correctly adjusted for this. Participants
were treated for up to six months and followed up for six months.
Fifteen participants with 16 ulcers were not included in the anal-
ysis; seven of these participants died during the course of the trial.
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Primary outcome: wound healing (proportion of wounds
completely healed)
Sipponen 2008 reported 17/27 (63.0%) ulcers in the spruce resin
group were healed by six months compared with 4/18 (22.2%)
in the hydrocolloid group. The RR for wound healing was 2.83
(95% CI 1.14 to 7.05) in favour of the spruce resin (Analysis 6.1).
GRADEassessment: low quality evidence downgraded once due
to attrition bias and once due to imprecision as the precision
estimates are likely to change upon correct analysis of data for
the outcome.
Primary outcome: adverse events
Sipponen 2008 did not report adverse events although the dropout
analysis was fully reported and this included data on events such
as deaths and skin reactions. These data were not further analysed.
Secondary outcome: change in bacterial resistance
Sipponen 2008 reported that of 18 ulcers assessed in each trial
arm one was found to be positive for MRSA at baseline. In both
cases this ulcer tested negative after one month (Analysis 6.2).
GRADE assessment: very low quality evidence downgraded due
to multiple sources of imprecision and due to attrition bias.
Summary of comparisons of antiseptics with non-
antimicrobial treatments (6 trials, 284 participants)
Four trials reported comparisons of povidone iodine with a dress-
ing without antimicrobial properties (hydrocolloid (Barrois 1993;
N = 78), hydrogel (Kaya 2005;N = 25), saline gauze (Kucan 1981;
N = 45), protease-modulating matrix (Nisi 2005; N = 80). Three
of these reported the proportion of wounds completely healed
(Barrois 1993; Kaya 2005; Nisi 2005). We had planned to pool
these studies in a random-effects meta-analysis. However, one of
the studies had substantive unit of analysis issues which would
have affected the pooled analysis (in Kaya 2005 49 ulcers were
analysed from 25 randomised participants). Barrois 1993 andNisi
2005 had such significant clinical heterogeneity in the application
of povidone iodine, as well as the comparators used, that it was
determined that pooling would not produce a meaningful result.
Whilst Barrois 1993 used a dressing impregnated with iodine, in
Nisi 2005 the iodine was applied as a daily disinfection in addition
to a non-antimicrobial dressing. One trial reported the primary
outcome of adverse events; Barrois 1993 reported no events.
There was no clear evidence that povidone iodine applied as a
dressing or as a disinfection solution improved the numbers of
pressure ulcers which healed in studies with short term follow-
up periods; data for two trials suggested comparator treatments
(hydrogel and protease-modulating matrix) were more effective
than antiseptics in healing ulcers. GRADE assessment: moderate
(comparison with protease-modulating dressings) or low (com-
parisonswith hydrocolloid and hydrogel) quality evidence. Low
quality evidence showed no clear evidence of a difference in in-
fection eradication between povidone iodine and saline gauze.
One trial compared cadexomer iodine to standard care in 38 par-
ticipants (Moberg 1983). The trial did not find evidence of a dif-
ference between the groups in wound healing or any secondary
outcomes. There were fewer adverse effects in the standard care
group. GRADE assessment: very low quality evidence down-
graded twice due to imprecision and once due to attrition bias.
One trial (37 participants with 45 ulcers) compared pine resin to
hydrocolloid dressings. Sipponen 2008 found a benefit of pine
resin in long-term wound healing. There was no evidence of a
difference in change in bacterial resistance. GRADE assessment:
low and very low quality evidence downgraded due to attrition
bias and imprecision.
2. Antiseptics compared with alternative antiseptics
(3 trials, 190 participants)
Comparison 7. Iodine sugar versus lysozyme ointment
One trial compared iodine sugar to lysozyme ointment. Imamura
1989 randomised 141 participants with stage I to IV pressure
ulcers to 3% povidone iodine sugar paste or lysozyme ointment.
Ulcers were treated and followed up for 8 weeks.
Primary outcome: wound healing (proportion of wounds
completely healed)
Imamura 1989 reported that 15/72 (21%) of participants’ ulcers
treated with iodine sugar healed compared with 12/69 (17%) ul-
cers in the lysozyme ointment group. There was no clear difference
between the groups; the RR for wound healing was 1.20 (95%
CI 0.60 to 2.37) (Analysis 7.1). GRADE assessment: very low
quality evidence downgraded twice for imprecision and once
for performance bias.
Primary outcome: adverse events
Imamura 1989 reported one adverse event in the iodine sugar
group and three in the lysozyme ointment group; one of these was
classed as serious. The RR for all adverse effects was 0.32 (95% CI
0.03 to 3.00) (Analysis 7.2). The denominators for this outcome
have been inferred from the ITT population.
Secondary outcome: change in wound size
Imamura 1989 reported the proportion of patients achieving a
reduction in wound area of at least 25% at one, two, four, six, eight
and the last week. At the last follow-up point 46/61 (75%) patients
in the iodine sugar group and 34/60 (57%) in the lysozyme group
had this reduction in area. The RR for this degree of reduction
was 1.33 (95% CI 1.02 to 1.73) in the direction of iodine sugar
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(Analysis 7.4). GRADE assessment: very low quality evidence
downgraded twice for imprecision and once for performance
bias.
Secondary outcome: change in infection status
Imamura 1989 reported change in infection status using a five
point scale from ”exacerbated“ to ”extremely improved“. At the
last follow-up point 28/61 (46%) participants in the iodine sugar
group were judged to be improved compared with 17/61 (28%)
in the lysozyme group (extremely improved 10 vs 3, moderately
improved 10 vs 6, slightly improved 8 vs 8). The RR of improve-
ment was 1.65 (95% CI 1.01 to 2.68) (Analysis 7.5). It is unclear
how these judgements were made. GRADE assessment: very low
quality evidence downgraded twice for imprecision and once
for performance bias.
Comparison 8. Iodine sugar versus gentian violet (1 trial, 19
participants)
One trial compared an iodine sugar treatment with a gentian violet
treatment in 19 participants with pressure ulcers in which MRSA
had been detected (Toba 1997). Treatment duration was reported
as 14 weeks.
Primary outcome: wound healing
Toba 1997 did not report this outcome
Primary outcome: adverse events
Toba 1997 reported that there were no adverse events in either
treatment group (Analysis 8.1).
Secondary outcome: change in wound size
Toba 1997 reported change in wound area. There was a decrease to
55.7% (SD 24.0) of the original wound area (a decrease of 44.3%)
in the iodine sugar group compared with a decrease to 44.6% (SD
12.9) of original size (a decrease of 55.4%) in the gentian violet
treatment group (MD −11.0; 95% CI −5.66 to 27.86) after 14
weeks (Analysis 8.1). GRADE assessment: low quality evidence
downgraded twice due to imprecision.
Secondary outcome: change in bacterial resistance
Toba 1997 reported that after 14 weeks the proportion of ulcers
which no longer had MRSA in wound cultures was 8/11 (72.7%)
in the iodine sugar group compared with 7/8 (87.5%) in the gen-
tian violet group (RR 0.83, 95% CI 0.53 to 1.30) (Analysis 8.2).
GRADE assessment: low quality evidence downgraded twice
due to imprecision.
Comparison 9. Polyhexanide dressing versus polyhexanide
swabs (1 trial, 30 participants)
One trial compared a polyhexanide-impregnated biocellulose
wound dressing plus foam dressing with a 20 minute cleansing
with polyhexanide swabs at dressing change followed by a foam
dressing (Wild 2012). The trial enrolled 30 hospital inpatients
and outpatients with stage II - IV pressure ulcers with long-term
intractable MRSA colonisation in spite of multiple previous dis-
infection attempts. Dressing changes were every two days, on av-
erage. Ulcers were treated for 14 days and then followed up for a
further three days (total follow-up of 17 days).
Primary outcome: wound healing
Wild 2012 did not report wound healing.
Primary outcome: adverse events
Wild 2012 did not report adverse events.
Secondary outcome: change in bacterial resistance
MRSA eradication was assessed at one and two weeks and at 17
days. After 14 and 17 days 15/15 (100%) ulcers in the dressing
group wereMRSA free compared with 10/15 (66.7%) in the swab
group. The RR for MRSA eradication was 1.48 (95% CI 1.02
to 2.13) in the direction of polyhexanide dressings (Analysis 9.1).
GRADE assessment: moderate quality evidence downgraded
once for imprecision.
Secondary outcome: pain
Wild 2012 reported pain using a visual analogue scale.Mean base-
line scores were 7.4 (SD 0.47) in the dressing group compared
with 6.8 (SD 0.53) in the swabs group. After 14 days the mean
score in the dressing group was lower at 1.3 (SD 0.36) than in
the swabs group, at 3.33 (SD 1.2). The mean difference between
the groups was −2.03 (95% CI −2.66 to −1.40), favouring the
dressing (Analysis 9.2). GRADE assessment: moderate quality
evidence downgraded once for imprecision.
Secondary outcome: resource use
Wild 2012 reported mean dressing change times as six minutes in
the dressing group and 25minutes in the swab group.Nomeasures
of variance were reported and no further analysis was possible.
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Summary of comparison of different antiseptics (3 trials, 190
participants)
One trial with 141 participants compared povidone iodine sugar
with lysozyme ointment. Imamura 1989 found no clear evidence
of a difference in wound healing but evidence of more patients
with a specified reduction in wound area and evidence of more
wounds showing ”improved“ infection status in the iodine sugar
group. GRADE assessment: low and very low quality evidence
downgraded for imprecision and performance bias.
One trial with 19 participants compared povidone iodine sugar
with gentian violet. Toba 1997 did not report the primary out-
comes of wound healing or adverse events and did not find clear
evidence of a difference in change in wound area or in eradica-
tion of MRSA.GRADE assessment: low quality evidence down-
graded twice due to imprecision.
One trial with 30 participants compared polyhexanide swabs with
polyhexanide dressings. Wild 2012 did not report the primary
outcomes of wound healing or adverse events. There was evidence
which favoured dressings for the eradication ofMRSA from ulcers
and for pain score at follow-up. GRADE assessment: moderate
quality evidence downgraded for imprecision.
3. Antiseptics compared with antibiotics (4 trials, 134
participants)
One trial compared povidone iodine with silver sulfadiazine
(Kucan 1981). Two trials compared a silver dressing with silver
sulfadiazine (Chuangsuwanich 2011; Chuangsuwanich 2013); as
different silver dressings were used in the trials they are presented
separately. One trial compared honey with ethoxy-diaminoacri-
dine plus nitrofurazone (a combination of an antiseptic and an-
tibiotic) (Yapucu Güne 2007).
Comparison 10. Povidone iodine versus silver sulfadiazine (1
trial, 45 participants)
One three-arm trial compared povidone iodine with silver sulfadi-
azine (Kucan 1981) in 45 hospitalised participants with infected
pressure ulcers; participants in the third arm were treated with
saline gauze (see comparison 3 and comparison 14).
Primary outcome: wound healing
Kucan 1981 did not report wound healing.
Primary outcome: adverse events
Kucan 1981 did not report adverse events.
Secondary outcome: infection eradication
At three weeks’ follow-up 7/11 (63.6%) ulcers treated with povi-
done iodine were judged to be free of infection compared with
15/15 (100%) ulcers treated with silver sulfadiazine. The RR for
infection eradication was 0.65 (95% CI 0.41 to 1.01). (Analysis
10.1). GRADE assessment: low quality evidence due to impre-
cision (downgraded twice for imprecision).
Comparison 11. Silver mesh versus silver sulfadiazine (1
trial, 40 participants)
One trial compared a silver mesh dressing with silver sulfadiazine
(Chuangsuwanich 2011). Forty inpatients and outpatients with
stage III or IV pressure ulcers were randomised to either silver
mesh dressing (changed every three days) or silver sulfadiazine
(dressings changed twice a day). Participants were followed up for
eight weeks. Cotton dressings were used as outer dressings in both
groups. Wound debridement was carried out as necessary. With-
out effect estimates for the reported outcomes full GRADE as-
sessments are difficult to provide but the quality of the evidence
may be downgraded as the small numbers of participants is
likely to result in imprecision.
Primary outcome: wound healing
Chuangsuwanich 2011 did not report wound healing.
Primary Outcome: adverse events
Chuangsuwanich 2011 reported no complications as a result of
treatment in either group. (RR not estimable).
Secondary outcome: change in wound size
Chuangsuwanich 2011 reported reduction in mean ulcer area. At
baseline the mean area was 12.17 cm² in the silver mesh group
and 22.82 cm² in the silver sulfadiazine group. At eight weeks the
mean area in the silver mesh group was 7.96 cm² (reduction of
4.21 cm² (34.6%)) compared with 18.22 cm² (reduction of 4.58
cm² (20.1%)). Nomeasures of variance were reported and the data
were not further analysed.
Secondary outcome: infection
Chuangsuwanich 2011 reported only qualitative microbiological
data; these were not extracted or analysed.
Secondary outcome: costs
Chuangsuwanich 2011 reported that the estimated mean cost of
treatment in the silver mesh group was USD 263 compared with
USD 1812 in the silver sulfadiazine group. Costs were estimated
as drug cost + outer dressing cost x time of dressing change/20.
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Comparison 12. Silver alginate versus silver sulfadiazine (1
trial, 22 participants)
One trial compared a silver alginate dressing with silver sulfadi-
azine (Chuangsuwanich 2013). This trial recruited participants
with stage III or IV pressure ulcers and randomised 22 partici-
pants of whom 20 with a total of 28 ulcers were analysed (two par-
ticipants died). Treatment duration and follow-up were for eight
weeks. Randomisation was conducted at the participant level but
the analysis of outcome data was conducted at the ulcer level. It
was not clear whether the analysis was correctly adjusted to ac-
count for this. None of the outcomes reported for this comparison
had sufficient data to enable us to calculate an effect size.Without
effect estimates for the reported outcomes full GRADE assess-
ments are difficult to provide, but the quality of the evidence
would likely be downgraded to take account of the fact that a
correct analysis of the data accounting for multiple ulcers for
some participants is likely to change any calculated effect sizes,
as well as the small numbers of participants which is likely to
contribute to imprecision.
Primary outcome: wound healing
Chuangsuwanich 2013 did not report wound healing.
Primary outcome: adverse events
Chuangsuwanich 2013 did not report adverse events although one
death in each group was recorded.
Secondary outcome: change in wound size
Chuangsuwanich 2013 reported reduction in mean ulcer area.
The mean wound area (in 15 ulcers) in the silver alginate group
was reduced by 44.27% (from a baseline of 36.11cm²) compared
with a reduction of 51.07% (from a baseline of 35.50cm²) in 13
ulcers in the silver sulfadiazine group. No measures of variance
were reported and the data were not further analysed.
Secondary outcome: infection
Chuangsuwanich 2013 reported only qualitative microbiological
data; these were not extracted or analysed.
Secondary outcome: costs associated with resource use
Chuangsuwanich 2013 reported mean overall cost of treatment
over eight weeks as USD 377.17 in the silver alginate group and
USD 467.74 in the silver sulfadiazine group. These figures were
calculated based on dressing unit costs, costs of dressing changes
and debridement and numbers of dressing changes. No measures
of variance were reported and the data were not further analysed.
Comparison 13. Honey versus ethoxy-diaminoacridine plus
nitrofurazone (1 trial, 27 participants)
Yapucu Güne 2007 enrolled 27 hospital patients with at least
51 stage II or III ulcers. Ninety-six percent of participants in
both groups had stage III ulcers. Participants were randomised to
honey or to ethoxy-diaminoacridine plus nitrofurazone dressings
and treated for up to five weeks. Follow-up duration was also five
weeks. Randomisation was conducted at the participant level but
outcome data were reported at the ulcer level. It was not clear
whether the analysis was appropriately adjusted to take this into
account.
Primary outcome: wound healing
Yapucu Güne 2007 reported that 5/25 (20%) ulcers in the honey
group healed compared with 0/ ≥26 (0%) in the comparison
group (25 ulcers assessed but one randomised participant with≥1
ulcer not included in analysis). There was no clear evidence of a
difference between groups: RR 11.42 (0.66 to 196.4) (Analysis
13.1). GRADE assessment: very low quality evidence (down-
graded twice for imprecision resulting from small numbers and
also for the fact that the precision of the estimate is likely to
change with correct analysis; and once for performance bias).
Primary outcome: adverse events
Yapucu Güne 2007 reported that no participant in either group
experienced adverse systemic or local side effects directly attributed
to treatment. The death of one participant was also reported.
Secondary outcome: change in wound size
YapucuGüne 2007 reported reduction inwound area. Twenty-five
ulcers in the honey arm showed amean 56% reduction in area after
five weeks compared with a mean 13% reduction in the ethoxy-
diaminoacridine plus nitrofurazone group. Measures of variance
were not reported and the data were not further analysed.
Summary of comparisons of antiseptics with antibiotics (4
trials, 134 participants)
One trial (N = 45) assessed povidone iodine (Kucan 1981). Kucan
1981 did not report wound healing or adverse events and did not
find clear evidence of a difference between the treatment groups
for infection eradication in the short-term. GRADE assessment:
low quality evidence downgraded twice due to imprecision.
Two trials (N=62) compared silver dressings (silvermesh and silver
alginate) with silver sulfadiazine. Neither reported wound healing.
One reported no adverse events and the other did not report this
outcome. Both trials reported data on wound area and costs but
no measures of variance were reported and the data could not be
fully analysed. No individual or pooled estimates of effect could
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be calculated and a GRADE assessment is difficult to provide.
However, the issues identified for the individual comparisons of
silver dressings with silver sulfadiazine (imprecision resulting
from small numbers and unadjusted analyses) would apply to
any assessment were an effect size to be calculated.
One trial (27 participants with at least 51 ulcers) compared honey
to ethoxy-diaminoacridine plus nitrofurazone dressings. Yapucu
Güne 2007 found a short-termbenefit of honey for wound healing
and reported no adverse events. The trial reported reduction in
wound area but without measures of variance that would allow
calculation of an effect estimate. GRADE assessment: very low
quality evidence (downgraded for imprecision resulting from
small numbers and unadjusted analyses and for performance
bias).
4. Antibiotics versus non-antimicrobial agents (1 trial,
45 participants)
Comparison 14. Silver sulfadiazine versus saline (1 trial, 45
participants)
One three-arm trial compared silver sulfadiazine with saline in
hospitalised participants with infected pressure ulcers, participants
in the third arm were treated with saline gauze (Kucan 1981) (see
comparisons 3 and 10).
Primary outcome: wound healing
Kucan 1981 did not report wound healing.
Primary outcome: adverse events
Kucan 1981 did not report adverse events.
Secondary outcome: infection eradication):
After three weeks 15/15 (100%) ulcers treated with silver sulfa-
diazine were judged to be free of infection compared with 11/14
(78.6%) ulcers treated with saline. There was no clear evidence
of a difference between groups: RR 1.26 (95% CI 0.94 to 1.69)
(Analysis 14.1). GRADE assessment: low quality evidence due
to imprecision (downgraded twice for imprecision).
Summary of comparisons of antibiotics with non-
antimicrobial interventions
One trial compared silver sulfadiazine to saline in 45 participants.
Kucan 1981 did not report the primary outcomes of wound heal-
ing or adverse events and did not find evidence of a difference be-
tween the treatment groups for infection eradication.GRADE as-
sessment: low quality evidence due to imprecision (downgraded
twice for imprecision).
D I S C U S S I O N
Summary of main results
This review includes all available RCT evidence for antiseptic/
antibiotic (anti-microbial) agents in the treatment of populations
with stage II and above pressure ulcers. Eleven trials with a total
of 437 participants were included.
Primary effectiveness outcome
All trials reporting wound healing did so as the proportion of
wounds completely healed; no trials reported eligible time-to-heal-
ing data.
Most wound-healing data were from comparisons of antiseptics
with non-antimicrobial agents. Trials compared povidone iodine
(Barrois 1993, Imamura 1989, Kaya 2005, Nisi 2005), cadex-
omer iodine (Moberg 1983), and pine resin (Sipponen 2008) to
a range of non-antimicrobial comparators. Each individual com-
parison was reported by a single trial. One trial comparing an
antiseptic (honey) with an antibiotic (nitrofurazone and ethoxy-
diaminoacridine) reported wound-healing data (Yapucu Güne
2007). None of the trials comparing an antibiotic with no treat-
ment or two antiseptics assessed wound healing.
Trials comparing povidone iodine to hydrogel (Kaya 2005) or to
a protease-modulating dressing (Nisi 2005) reported a reduction
in the ’risk’ of healing in the povidone iodine group (that is they
favoured the comparator treatment) however the GRADE assess-
ments were low quality and moderate quality respectively. This
indicates that further research is likely or very likely to have an
important impact on our confidence in the estimate of effect and
may, or is likely to, change the estimate of effect. Low quality ev-
idence from a trial comparing povidone iodine and a hydrocol-
loid dressing showed no clear evidence of a difference between the
treatments (Barrois 1993). There was also low quality evidence of
a benefit of pine resin salve compared with a hydrocolloid dressing
(Sipponen 2008). Again, further research is likely to change the
estimates of effect for these comparisons.
There was very low quality evidence of no clear evidence of a dif-
ference between honey and the combination of nitrofurazone and
ethoxy-diaminoacridine treatment (Yapucu Güne 2007). Two tri-
als which found no clear evidence of a difference between cadex-
omer iodine compared with standard care (Moberg 1983) or be-
tween iodine sugar and lysozyme ointment (Imamura 1989) were
also assessed as representing very low quality evidence. In these
cases it is likely that the true effect is substantially different from
the estimates of effect in the trials.
In most instances the quality of the evidence was primarily im-
pacted by high levels of imprecision as a consequence of compar-
isons being assessed by single, small and underpowered trials.
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Primary safety outcome
The primary safety outcome was adverse effects. Six trials reported
extractable data (Barrois 1993; Chuangsuwanich 2011; Imamura
1989; Moberg 1983; Toba 1997; Yapucu Güne 2007), four of
which stated that there were no adverse effects. No GRADE as-
sessment was possible but substantial limitations were identified
which an assessment would have taken into account. There was
very low quality evidence showing no clear evidence of a difference
in patients treated with standard care compared with cadexomer
iodine (Moberg 1983). Several trials reported some partial data on
adverse events but did not make it clear whether this related to all
participants.
Secondary outcomes
Limited secondary review outcomes were reported in the included
studies. All studies were small and these comparisons were invari-
ably underpowered and subject to imprecision.
The trials that reported change in wound size as a continuous
outcome did not report any clear evidence favouring any partic-
ular antiseptic/anti-microbial treatments. Where a GRADE as-
sessment was possible this was low quality evidence (comparison
of povidone iodine with gentian violet, Toba 1997) or very low
quality evidence (cadexomer iodine compared with standard care,
Moberg 1983). Further research is likely to change or very likely to
substantially change these estimates of effect. Where no GRADE
assessment was possible (comparison of silver dressings with sil-
ver sulfadiazine (Chuangsuwanich 2011; Chuangsuwanich 2013);
and of honey versus nitrofurazone and ethoxy-diaminoacridine
(Yapucu Güne 2007)) we identified substantial limitations which
a GRADE assessment would have taken into account.
Four trials measured the resolution of infection (in three trials
all ulcers were infected at baseline); in one trial there was some
evidence of more MRSA eradication (at two weeks) in partici-
pants with an ulcer treated with a polyhexanide dressing compared
with a polyhexanide swab (Wild 2012). This was classed as mod-
erate quality evidence due to some imprecision; further research
may change the estimate of effect. There was low quality evidence
showing no clear evidence of a difference between interventions
in the following comparisons: pine resin salve versus hydrocolloid
dressing (Sipponen 2008), povidone iodine sugar versus gentian
violet (Toba 1997), and povidone iodine versus silver sulfadiazine
versus saline (Kucan 1981). Further research is likely to change
these estimates of effect.
There was moderate quality evidence of less pain for patients
treated with polyhexanide dressing compared with a polyhexanide
swab (Wild 2012); and very low quality evidence of no conclusive
findings in the comparison of cadexomer iodine with standard care
(Moberg 1983).
Overall completeness and applicability of
evidence
Most of the participants in the included trials were hospitalised
older people. Where reported they had high levels of comorbidity.
They are likely to be representative of patients seen in clinical
practice.
Quality of the evidence
RCTs need to be adequately powered so that they are able to de-
tect treatment effects of a specified size if they exist. This means
that sample size calculations should be used to help estimate the
number of people recruited to a trial. Trials should also have an
adequate follow-up period so that there is sufficient time for im-
portant outcome events - such as wound healing - to occur. All
the trials included in this review were small and all except one
had a short follow-up period of eight weeks or less. As a result
of this, only around half the trials (6/11) reported any wound-
healing data, and none were able to report appropriate time-to-
wound-healing data.
All studies included in this review were at high or unclear risk of
bias across multiple domains. In general studies did not follow
good practice for conduct and reporting guidelines (e.g. CON-
SORT (Schulz 2010)). Key areas of good practice are the robust
generation of a randomisation sequence, robust allocation con-
cealment, and blinded outcome assessment where possible. All this
information should be clearly included in the trial report, as trial
authors should anticipate the inclusion of their trials in systematic
reviews. Studies should also clearly report how they planned to
collect adverse event data and how this process was implemented
in a standardised way across treatment arms. Where possible anal-
ysis of all data should be conducted on an intention-to-treat basis
and measures of variance such as the standard deviation or stan-
dard error of the means should be reported. Trials should be ap-
propriately designed and correctly analysed to take account of any
clustered data; where this is not the case the reliability of results
is uncertain. As far as possible trialists should take steps to reduce
missing data.
Potential biases in the review process
This review considered as much evidence as possible. It was not
limited by language or publication status. One of the included
studies was published in Japanese (Toba 1997), as were several
studies subsequently excluded from the review; other excluded
studies were in German or Spanish. Many of the included stud-
ies were conducted in countries in which English is not the first
language. Both studies awaiting classification are likely to be eli-
gible for inclusion but require translation assistance from Italian
(Bigolari 1991), or Portuguese (Goldmeier 1997) (we have not
yet obtained the full text for this trial). It is possible that there
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may be unpublished data that we have been unable to identify.
In many of the included studies one or more of the antimicrobial
agents was being evaluated as a control/standard care arm. This
was particularly the case for the assessment of povidone iodine and
silver sulfadiazine. Because of this the presence of publication bias
would perhaps be seen in an undue representation of small trials
with negative rather than positive findings for these treatments.
Whilst we acknowledge the possibility of publication bias despite
our attempts to locate unpublished studies, there were too few
trials to test for its presence.
Only two studies stated that they were funded by commercial
companies (Nisi 2005; Wild 2012). However another two trials
acknowledged some formof assistance froma company; in one case
this was supply of one of the assessed treatments (Chuangsuwanich
2013); in the other the form of assistance was unclear (Moberg
1983). One other trial reported that its authors had subsequently
formed a company in order to commercially develop the tested
product (Sipponen 2008).
Agreements and disagreements with other
studies or reviews
No other review has specifically focused on antimicrobial agents
for pressure ulcers. Our review overlaps in content with general
reviews of treatments for pressure ulcers and broader categories of
wounds and with reviews of specific antiseptic agents for pressure
ulcers or wounds generally. The category of antiseptics also covers
both dressings and wound cleansing and therefore reviews in both
these areas. We discuss the agreements and disagreements with the
major reviews which we are aware of across these categories but
acknowledge that there may be other reviews which we do not
discuss.
General pressure ulcers/wounds
Smith 2013 included trials included in our review (Kaya 2005;Nisi
2005; Sipponen 2008; Yapucu Güne 2007). The review authors
also included Rhodes 2001 which was excluded by this review
because of a quasi-randomised design. It was difficult to determine
whether other trials were identified and subsequently excluded
or were not identified. Smith 2013 had a much broader scope
than the present review, covering multiple types of treatments and
includingnon-randomised designs aswell asRCTs; thereforemany
of the studies identified and excluded by our review were included
in theirs.
Reddy 2008 included a trial of oxyquinolone ointment which
was excluded from this review because of the high proportion of
included participants with stage I pressure ulcers (Gerding 1992)
and the trial by Rhodes 2001. Two additional trials were included
which were excluded from our review (Kim 1996; Yastrub 2005);
Kim 1996 included a high proportion of stage I ulcers whilst
Yastrub 2005 did not report any outcomes relevant to our review.
Reddy 2008 included five trials also included in our review (Kaya
2005; Moberg 1983; Nisi 2005; Sipponen 2008; Yapucu Güne
2007). Several of the other trials in our review were published after
Reddy 2008 was completed; it is not clear whether the remaining
trials were identified and excluded or were not identified. As with
Smith 2013 the scope was much broader than the present review
and therefore many of the studies we excluded as not assessing a
relevant interventionwere included in theirs. There was no overlap
with Moore 2013b’s review of wound cleansing.
Honey
Jull 2013 reviewed honey for multiple wound types. The review
authors included one trial in pressure ulcers which was excluded
here because the great majority of the pressure ulcers were stage I
(Weheida 1991). Because of unit of analysis issues this review also
excluded the one RCT assessing honey which is included in this
review (Yapucu Güne 2007).We identified these issues and down-
graded the quality of the evidence in our GRADE assessment.
Silver
Vermuelen 2007 and Storm-Versloot 2010’s reviews of silver were
carried out before the publication date of trials assessing silver
included in this review. Neither included any trials in pressure
ulcers.
Iodine
Vermuelen2010’s review of iodine inwound care included three of
the trials included in this review (Kaya 2005; Kucan 1981;Moberg
1983). The two other trials of iodine in the current review were
not included (Barrois 1993; Nisi 2005); it was not clear whether
they were identified and then excluded.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A comprehensive review of current evidence did not find con-
vincing evidence in favour of the use of any particular antimicro-
bial treatment compared with other antimicrobial treatment or to
other comparators for pressure ulcers. Where differences in out-
comes which matter (including wound healing) were found, these
sometimes favoured the comparator treatment which did not have
antimicrobial properties. However, the quality of the evidence var-
ied from moderate to very low; all of the evidence was subject to
some limitations. There is no randomised evidence on the use of
systemic antibiotics for people with pressure ulcers.
Implications for research
Currently there is no consistent evidence of a difference in pres-
sure ulcer healing between ulcers treated with interventions with
antimicrobial properties and those treated with alternative inter-
ventions, or between different antimicrobial treatment options.
In terms of treatment choice, any investment in future primary
research must maximise its value to patients, health-care profes-
sionals, service commissioners and other decision-makers. Given
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the large number of treatment options, the design of future tri-
als should be driven by high-priority questions from patients and
other decision-makers. It is also important for research to ensure
that the outcomes that are collected in research studies are those
that matter to patients, carers and health professionals. Where
trials are conducted, good practice guidelines must be followed
in their design, implementation and reporting. Further evidence
synthesis (overviews of reviews, network meta-analysis or both)
may aid decision-making about the choice of topical treatments
for pressure ulcers, including the decision whether to use inter-
ventions with antimicrobial properties.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barrois 1993
Methods Multicentre parallel RCT (countries not reported)
Duration: 56 days
Unit of randomisation: participant
Unit of analysis: participant
Participants Inclusion criteria: people presenting with open necrotic pressure ulcers
Participants: 76 people with ulcers;
Ulcer size (cm²): 15 (reported comparable between groups)
Age, gender, ulcer location, ulcer stage not reported (”open necrotic pressure sore“ in-
terpreted by review authors as stage II or higher)
Interventions Intervention arm 1: gauze (Tulle) with povidone iodine
Intervention arm 2: hydrocolloid dressing (Granuflex)
Co-interventions: cleansing with saline and debridement with forceps if necessary in
both groups
Outcomes Primary outcome: proportion of wounds completely healed
Primary outcome: adverse events
Secondary outcome: resource use (dressings per week)
Notes Reported in abstract only; authors not contacted due to date of publication
Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reported in abstract only
Allocation concealment (selection bias) Unclear risk Reported in abstract only
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported in abstract only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”Thirty-eight patients received
Granuflex and 38 received a Tulle dress-
ing impregnated with povidone-iodine an-
tiseptic ointment......Two patients receiv-
ing Granuflex and five patients receiving
the control dressing dropped out of the trial
due to a deterioration in the pressure sore“
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Barrois 1993 (Continued)
Comment: 7 of 72 patients were not in-
cluded in the analyses; reasons specified
Selective reporting (reporting bias) Unclear risk Reported in abstract only
Other bias Unclear risk Reported in abstract only
Chuangsuwanich 2011
Methods Country where data collected: Thailand
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: participant
Duration: 8 weeks
Participants Inclusion criteria: people with stage III/IV pressure ulcers
Exclusion criteria: not reported
Participants: 40 hospital inpatients and outpatients
Mean age (years): 62.6 vs 69.1
Number of Males: 8/20 vs 9/20
Ulcer size (cm²): 12.17 vs 22.82
Ulcer location: sacrum 16/20 vs 14/20, trochanter 1/20 vs 5/20, ischium 3/20 vs 1/20
Ulcer stages: distribution not reported
Interventions Intervention arm 1: silver mesh dressing changed every 3 days
Intervention arm 2: silver sulfadiazine cream changed twice daily
Co-interventions: wound cleansing at every dressing change and cotton gauze outer
dressing in both groups. Debridement as required
Outcomes Primary outcome: adverse events
Secondary outcome: wound area reduction
Secondary outcome: infection (qualitative bacteriological data only)
Notes Funding NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The ulcers graded III-IV were di-
vided randomly by computer into two 20
patient-groups.”
Comment: Computer generated randomi-
sation sequence
Allocation concealment (selection bias) Unclear risk Quote: “The ulcers graded III-IV were di-
vided randomly by computer into two 20
patient-groups.”
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Chuangsuwanich 2011 (Continued)
Comment: Although appropriate genera-
tion of sequence no information on con-
cealment of allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The ulcer healing was assessed by
using the Pressure Ulcer Scale for Healing
(PUSH 3.0) every two weeks also. PUSH
tool was used for evaluation of the condi-
tion of the wounds.”
Comment: No indication if assessment was
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Forty patients enrolled to the
present study. Twenty patients in each
group finished the eight-week study.”
Comment: Outcome data reported for all
randomised patients
Selective reporting (reporting bias) Unclear risk Comment: No direct quote but primary/
secondary outcomes not stated a priori
Other bias Unclear risk Quote: “Wounds were debrided as neces-
sary.”
Comment: not clear how often this hap-
pened or how it differed between groups
Chuangsuwanich 2013
Methods Country where data collected: Thailand
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: ulcer
Duration: 8 weeks
Participants Inclusion criteria: hospital outpatients aged over 20 years and able to visit hospital
regularly with stage III or IV pressure ulcers which were sacral or trochanter, not necrotic
or with clinical signs of infection
Exclusion criteria: no known sensitivity to treatment/control, no glucose-6-phosphate
dehydrogenase deficiency
Participants: N = 22 (randomised), 20 (analysed) (28 ulcers)
Mean age (years): 76 vs 73 years
Number of males: 4/11 in each arm
Ulcer stage: stage III 8/13 vs 8/15; IV: 5/13 vs 7/15
Ulcer location: sacral 9/13 vs 10/15, trochanter 4/13 vs 5/15
Ulcer size (cm²): Not reported
Interventions Intervention arm 1: silver alginate dressing changed every 3 days, wound cleansing at
every dressing change
Intervention arm 2: silver sulfadiazine cream changed once per day
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Chuangsuwanich 2013 (Continued)
Cointervention: wound cleansing at every dressing change; debridement as required
Outcomes Secondary outcome: wound area reduction
Secondary outcome: infection (qualitative bacteriological data only)
Notes Funding: NR but silver alginate product donated by B Braun Co. Ltd, Thailand
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The enrolled patients were ran-
domly divided into two groups by drawing
from a sealed envelope for each group….
All of the 20 patients were randomly di-
vided into the two groups according to the
study protocol.”
Comment: Unclear how randomisation se-
quence was generated
Allocation concealment (selection bias) Unclear risk Quote: “The enrolled patients were ran-
domly divided into two groups by drawing
from a sealed envelope for each group….
All of the 20 patients were randomly di-
vided into the two groups according to the
study protocol.”
Comment: Unclear whether envelopes
were opaque
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “After the wound was cleansed by
nurse, it was examined and scored by an
independent operator, plastic surgeon, who
was blinded to the dressing protocol.”
Comment: blinding appears to have oc-
curred
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: flow diagram shows 22 patients
randomised, 2 died during study, data from
20 were analysed
Selective reporting (reporting bias) Low risk Comment: Outcomes reported inmethods
present in results
Other bias High risk No specific quote: Randomisationwas con-
ducted at a patient level but the analysis was
carried out at the level of the ulcer; it did
not appear that paired data (multiple ul-
cers from individual participants) were ac-
counted for in the analysis
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Imamura 1989
Methods Country where data collected: Japan
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: participant
Duration: 8 weeks (8 weeks follow-up duration)
Participants Inclusion criteria: participants with pressure ulcers stages 1-4 treated in hospital
Exclusion criteria: not reported
Participants: N = 141 (randomised); 139 analysed of whom 109 had stage 2 or above
pressure ulcers
Mean age: Not reported
Number of males: 37/71 vs 30/68
Ulcer stage: stage 1 16 vs 14; stage 2 or 3 31 vs 26; stage 4 24 vs 28
Ulcer location: sacrum 51 vs 45; ischium 6 vs 6; back 6 vs 4; greater trochanter 4 vs 4;
ilium 1 vs 6; other 3 vs 4
Ulcer size (cm²): 25.48 (SE 4.34) vs 29.29 (SE 4.65)
Interventions Intervention arm 1: KT-136 (sugar (70g/100g) and povidone iodine (3g/100g)) oint-
ment applied directly on to the wound or to the gauze sheet applied to the wound.
Application once or twice a day
Intervention arm 2: lysozyme ointment (5g/100g) applied directly on to the wound or
to the gauze sheet applied to the wound. Application once or twice a day
Cointerventions: none reported
Outcomes Primary outcome: proportion of wounds completely healed
Primary outcome: adverse events and serious adverse events
Secondary outcome: wound area reduction
Secondary outcome: infection
Notes Trial published entirely in Japanese; assessment for inclusion, data extraction and risk of
bias assessment all conducted by one review author
Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table used
Allocation concealment (selection bias) Low risk Central telephone allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding was used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No reasons were provided for missing data
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Imamura 1989 (Continued)
Selective reporting (reporting bias) Unclear risk This was unclear due to poor reporting
Other bias Unclear risk Multiple sources of uncertainty
Kaya 2005
Methods Country where data collected: Turkey
Parallel group trial
Unit of randomisation: participant
Unit of analysis: ulcer
Duration: trial duration not reported; reported treatment duration ranged up to 106
days; primary outcome reported at durations from 21 to 85 (arm 1) and 15 to 83 (arm
2) days
Participants Inclusion criteria: spinal-cord injury patients with pressure ulcers
Exclusion criteria: not reported
N = 27 (49 ulcers)
N males: 24/27 (group distribution NR)
Mean age (years): 35.3 vs 29.7 years
Ulcer size (cm²) 4.13 vs 6.45
Ulcer stage: I: 6/25 vs 6/24, II: 17/25 vs 17/24; III: 2/25 vs 1/24
Ulcer location: sacral 6/25 vs 7/24, ischia 6/25 vs 3/24, heel 6/25 vs 2/24, greater
trochanter 3/25 vs 6/24, iliac crest 0/25 vs 4/24, knee 1/25 vs 2/24, head of fibula 0/25
vs 2/24, lateral malleolus 2/25 vs 0/24, dorsum of foot 0/25 vs 1/24
All ulcers were non-infected; patients were hospitalised
Interventions Intervention arm 1: hydrogel-type dressing (Elasto-Gel) changed every 4 days or more
frequently if membrane contaminated or non-occlusive
Intervention arm 2: povidone-iodine-soaked gauze changed daily
Cointerventions: necrotic areas debrided
Outcomes Primary outcome: proportion of wounds completely healed
Notes Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “We prospectively studied 27 hos-
pitalised patients with spinal-cord injury
(24 males and three females) who had a to-
tal of 49 pressure ulcers. Each patient was
randomly assigned to one of two groups.”
Comment: how randomised unclear
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Kaya 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “We prospectively studied 27 hos-
pitalised patients with spinal-cord injury
(24 males and three females) who had a to-
tal of 49 pressure ulcers. Each patient was
randomly assigned to one of two groups.”
Comment: no information on conceal-
ment of allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Ulcers were graded using the
NPUAP system to ensure consistency in
both groups. Surface area was used as an
indicator of healing, and measured in cm².
”
Comment: no indication if assessment was
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “For ulcers that healed during the
hospital stay, the rate of healing (cm²/
days) was calculated as the initial surface
area (cm²) divided by healing time (days)
. Where patients were discharged before
healing was complete, it was calculated by
subtracting the ulcer surface area at the
most recent examination from the baseline
surface area, then dividing this by the treat-
ment time (days) while in hospital.”
Comment: outcome data reported for all
randomised patients, but it is unclear how
many patients’ data were estimated
Selective reporting (reporting bias) Unclear risk Quote: ”For each lesion, we recorded loca-
tion, rate of healing, healing time and treat-
ment time.Healing time (days)was defined
as the time from the start of treatment to
when 100% epithelialisation was observed.
“
Comment: outcomes appear consistently
listed or reported throughout text. Not
clear what is primary and secondary out-
come
Other bias High risk Quote: “We prospectively studied 27 hos-
pitalised patients with spinal-cord injury
(24 males and three females) who had a to-
tal of 49 pressure ulcers .”
Comment: randomisation was conducted
at a patient level but the analysis was carried
out at the level of the ulcer; it did not ap-
pear that paired data (multiple ulcers from
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Kaya 2005 (Continued)
individual participants) were accounted for
in the analysis
Kucan 1981
Methods Country where data collected: USA
Parallel group trial (three arms)
Unit of randomisation: participant
Unit of analysis: participant
Duration: 3 weeks
Participants Inclusion criteria: hospitalised patients with an infected PU on the sacral, ischial or
femoral trochanteric areas. Infection was defined as bacterial count > 10 bacteria/g
tissue
Exclusion criteria: patients with concomitant infections outside the wound, acute cel-
lulitis surrounding the ulcer or radiographic bone involvement beneath the ulcer were
excluded
N = 45*
Mean age (years): NR; range 16 to 102. Further details not reported but no statistically
significant difference between groups on age, sex, paraplegia/tetraplegia or ulcer location
Interventions Intervention arm 1: silver sulfadiazine (Silvadene cream) applied every 8 hours and
covered with 2 layers fine mesh gauze
Intervention arm 2: povidone iodine (Betadine solution) saturated coarse mesh gauze
dressing changed every 6 hours
Intervention arm 3: 0.9% sodium chloride solution: cleansing with sterile saline then
coarse mesh gauze dressing saturated with solution, changed every 4 hours
Cointerventions: debridement of necrotic tissue as indicated. Systemic antibiotics only
for intercurrent infections (15 patients received them, distributed equally)
Outcomes Secondary outcome: change in infection status (eradication of infection)
Notes *Numbers randomised to each arm were not reported, numbers analysed were reported
per arm together with total number of dropouts
Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the patients were assigned to one
of three treatment groups according to a
computer-generated randomized table”
Comment: computer-generated randomi-
sation sequence
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Kucan 1981 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “the patients were assigned to one
of three treatment groups according to a
computer-generated randomized table”
Comment: no further information to indi-
cate concealment of allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the biopsy specimen was delivered
to the microbiologist who had no knowl-
edge of which treatment the patient was re-
ceiving”
Comment: the assessingmicrobiologistwas
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “although 45 patients were in-
cluded in the study initially, only 40 were
finally included in the efficacy analysis. The
40 patients were divided among the treat-
ment groups as follows: silver sulfadiazine
cream, 15; povidone-iodine solution, 11;
and physiologic saline, 14”
Comment: 5/45 withdrawals but reasons
for withdrawals and group allocations not
reported
Selective reporting (reporting bias) Low risk Comment: no direct quotes but all stated
outcomes of interest were reported
Other bias Low risk Comment: no direct quotes but no evi-
dence of additional sources of bias. Sys-
temic antibiotic therapy was assessed and
did not differ between groups
Moberg 1983
Methods Country where data collected: Sweden
Parallel group RCT but included provision for cross-over between treatments*
Unit of randomisation: participant
Unit of analysis: participant
Duration: 8 weeks
Participants Inclusion criteria: hospitalised patients with pressure ulcer
Exclusion criteria: patients who were “moribund”, who had suspected malignancy or
a psychiatric illness or other condition which could prevent informed consent were
excluded
N = 34
N males 8/34 (group distribution not reported)
Mean age (years) 80.1 vs 72.6;
Ulcer size/stage: not reported, 8/18 versus 10/16 classed as ”deep“, 10/18 versus 6/16
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Moberg 1983 (Continued)
classed as ”superficial“; mean duration of ulcers: 6.2 months; review author judgement
that ulcers were stage II or above
Ulcer location: not reported
Interventions Arm 1: “standard treatment” as used in each hospital. This was individualised for each
patient and depended on the appearance of the ulcer and surrounding skin. It included
saline dressings, enzyme-based debriding agents and nonadhesive dressings
Arm 2: cadexomer iodine applied daily in a 3 mm layer and removed after 24 hours with
water/saline/wet swab
Cointerventions: Attention to nutrition, hygiene improvement, removal of localised
pressure with specialised mattresses, turning and optimal mobilisation
Outcomes Primary outcome: proportion of wounds completely healed
Primary outcome: adverse events
Secondary outcome: wound area reduction
Secondary outcome: pain
Notes *Cross-overs between treatments did not appear to occur at prespecified time-points.
Data for primary outcome were reported on an ITT basis
Funding: NR but assistance from personnel at TIL Medical Ltd acknowledged
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were allocated blindly and
at random for treatment”
Comment: no information on how the ran-
domisation sequence was produced or con-
ducted
Allocation concealment (selection bias) Unclear risk Quote: “patients were allocated blindly and
at random for treatment”
Comment: no information on how the ran-
domisation sequence was produced or con-
ducted
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no specific quote but no infor-
mation on whether assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “After three weeks.... three of the
patients receiving standard treatment were
switched to cadexomer iodine because of
lack of response.... Two patients whose ul-
cers did not respond to cadexomer iodine
were switched to standard treatment.....
Two patients whose ulcers did not respond
to the standard treatment dropped out of
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Moberg 1983 (Continued)
the trial after three weeks”
Comment: 7/34 patients were reported as
dropping out or switching treatment (rea-
sons were given); pain data were unavail-
able for a further 1 patient
Selective reporting (reporting bias) Low risk Comment: no specific quote but outcomes
specified in the methods were all reported
in the results
Other bias Unclear risk Quote: “patients were allocated blindly and
at random for treatment with cadexomer
iodine or for the standard treatment used
in each hospital. Standard treatment was
individualized for each patient”
Comment: because standard treatment was
not fully reported and varied between pa-
tients it is unclear whether it included
concomitant therapies which may have af-
fected the results
Nisi 2005
Methods Country where data collected: Italy
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: participant
Duration: trial duration not reported; reported durations of randomised treatments 2 to
8 weeks (pre-randomisation phase 1 to 6 weeks)
Participants N = 80
Inclusion criteria: patients with pressure wounds
Exclusion criteria: decompensating diabetes, hypertension, severe hypoalbuminosis, clin-
ical evidence of arterial/venous insufficiency, haematocrit values below 4%/36% for
males/females, treatment with steroids or immunosuppressant drugs
N males: 53/80
Mean age (years): 45 (group distribution not reported)
Ulcer stage: II-IV (numbers and group distribution not reported)
Ulcer location: sacrum 28/80; back 2/80; upper limbs 8/80; lower limbs 42/80
(trochanteric area 24; heel 18); (group distribution not reported)
Ulcer size (cm²): Not reported
Interventions Intervention arm 1: protease-modulating matrix treatment changed 2 or 3 times weekly
according to exudation
Intervention arm 2: daily disinfection with 50% povidone iodine solution, saline wash
and dressings with Vaseline gauze
Cointervention: treatment initiated after wounds were cleansed (no necrosis and no
infection) using
surgical debridement and disinfection with PVP-I solution (treatment period of 1 to 6
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Nisi 2005 (Continued)
weeks). All dressings covered with hydropolymer patch during randomised treatment
phase
Outcomes Primary outcome: proportion of wounds completely healed
Secondary outcome: resource use (hospital stay)
Secondary outcome: resource use (dressing changes)
Notes Funding: Systagenix Ltd (manufacturer of PMM treatment Promogran)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote ”a cohort of 80 selected patients was
randomly divided into two groups“
Comment: no information on how the ran-
domisation was performed
Allocation concealment (selection bias) Unclear risk Quote ”a cohort of 80 selected patients was
randomly divided into two groups“
Comment: no information on whether al-
location concealment was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no direct quote but no infor-
mation on whether assessors were blind to
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no direct quote but data were
reported for all 80 randomised patients
Selective reporting (reporting bias) Unclear risk Comment: no direct quote but outcomes
were not prespecified
Other bias Low risk No evidence of other sources of bias
Sipponen 2008
Methods Country where data collected: Finland
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: ulcer
Duration: 6 months
Participants Inclusion criteria: patients with one or several severe pressure ulcers (stage II-IV) with
or without infection
Excusion criteria: patients with life expectancy of less than 6 months or with a malignant
disease
N: 37 participants with 45 ulcers (randomised); 22 participants with 29 ulcers (analysed)
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Sipponen 2008 (Continued)
N males: 6/13 vs 3/9
Mean age (years): 80 vs 74
No statistically significant difference between groups on ulcer location, stage or size but
these were not reported; ulcer area was also not reported.*
Interventions Intervention arm 1: spruce resin salve mixed (1 mm thick) between loose sterile cotton
gauze changed every third day. Changed daily if infected or discharge present
Intervention arm 2: sodium carboxymethylcellulose hydrocolloid polymer with or with-
out ionic silver (Aquacel or Aquacel AG) Aquacel Ag used where clinical and laboratory-
confirmed evidence of infection. Changed every third day or daily if discharge present
Cointerventions: oral antibiotics only if wound infected
Outcomes Primary outcome: proportion of wounds completely healed
Secondary outcome: infection (eradication)
Notes *Demographic data refer to participants included in analysis only
Funding: NR but authors have now founded a company to commercially develop the
resin salve
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was in permuted
block sizes of four. The randomization pro-
tocol was designed by a specialist in bio-
metrics (S.S.). The responsible physicians
in the primary care hospitals allocated pa-
tients to receive either resin treatment or
control treatment according to the ran-
domization list (closed envelopes).”
Comment: appropriate block randomisa-
tion
Allocation concealment (selection bias) Unclear risk Quote: “The responsible physicians in the
primary care hospitals allocated patients to
receive either resin treatment or control
treatment according to the randomization
list (closed envelopes).“
Comment: unclear if sealed envelopes were
opaque
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “As there are, by necessity, dis-
cernible properties of the resin salve (e.g.
fragrance and consistency), the treatment
could not be blinded.” “Eleven indepen-
dent physicians, one in each primary care
centre, collected the data during the study
period (6 months)”
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Sipponen 2008 (Continued)
Comment: Clear that patients/physicians
not blinded but unclear if outcome asses-
sors were blinded as they are described as
‘independent’
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “A prospective, randomized, con-
trolled multicentre trial involving 37 pa-
tients ... Thirteen patients of the resin
group and nine patients of the control
group completed the 6-month trial”
Comment: 15/37 patients did not com-
plete the trial and were not included in the
analysis. Reasons for these were compre-
hensively provided but the level of attrition
remains high
Selective reporting (reporting bias) Low risk Comment: no specific quote but all out-
comes specified in methods section are re-
ported
Other bias High risk Comment: no specific quote: randomisa-
tionwas conducted at a patient level but the
analysiswas carried out at the level of the ul-
cer; it did not appear that paired data (mul-
tiple ulcers from individual participants)
were accounted for in the analysis
Toba 1997
Methods Country where data collected: Japan
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: participant
Duration: 14 weeks (duration), 2 years (follow-up)
Participants Inclusion criteria: detected MRSA from ulcers in previous month
Excusion criteria: not reported
N: 19 participants
N males: 0/19
Mean age (years): 83.5 ± 3.0 years old
Participants were hospital inpatients with cerebrovascular disorder, without diabetes,
malignant tumours and liver dysfunctions
Interventions Intervention arm 1: GVcAMP (base: polyethylene glycol (SOLBASE), 0.1% Gentian
Violet (Piokutanin): Dibutyryl cAMP (Actsin) = 1:1)
Intervention arm 2: IS (Iodine Sugar(U-PASTA))
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Toba 1997 (Continued)
Outcomes Primary outcome: adverse events
Secondary outcome: wound area reduction
Secondary outcome: infection (microbiological data only)
Notes Trial published in Japanese; data extraction and risk of bias assessment conducted by
single translator. Assessed as meeting inclusion criteria for pressure ulcers (and stages) by
translator
Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by using a table of random
numbers
Allocation concealment (selection bias) Unclear risk Using a table of random numbers which
was unclear whether open or not
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no dropouts
Selective reporting (reporting bias) Unclear risk The protocol is not available, insufficient
information to permit judgement
Other bias Unclear risk Some sources of uncertainty
Wild 2012
Methods Country of data collection: Austria
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: participant
Duration: 14 days (treatment); 17 days (follow-up)
Participants Inclusion criteria: patients with pressure ulcers with long-term intractableMRSA coloni-
sation despite multiple previous disinfection attempts
Exclusion criteria: NR
N: 30
Mean age (years):70.9 vs 66.5
N male: 7/15 vs 8/15
Ulcer stage: stage 2: 3/15 vs 2/15, stage 3: 6/15 vs 6/15 sacral/ischial; stage 4: 7/15 vs 7/
15 (all sacral)
Ulcer location: heel 3/15 vs 2/15; sacral 11/15 vs 10/15; ischial 1/15 vs 3/15
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Wild 2012 (Continued)
Mean ulcer area (cm²) 47.67 vs 35.80
Interventions Intervention arm 1: biocellulose wound dressing + polyhexanide covered with foam
dressing; dressing changes every 2 days (on average)
Intervention arm 2: cleansing for 20 min with polyhexanide swabs and then a foam
dressing; dressing changes every 2 days (on average)
Cointerventions: two-week washout period following previous disinfection attempts.
Periwound skin protected with zinc cream where applicable
Outcomes Secondary outcome: infection (eradication)
Secondary outcome: pain
Secondary outcome: resource use (dressing change times)
Notes Funding: Lohmann & Rauser GmbH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization, using a com-
puter-generated code, occurred following
patient consent and eligibility confirma-
tion”
Comment: computer-generated randomi-
sation sequence
Allocation concealment (selection bias) Unclear risk Quote: “Upon inclusion to the study by
opening sealed envelopes, which contained
information on the proposed treatment,
patients were assigned to 1 of the 2 groups”
Comment: although sealed envelopes were
used it was unclear if they were opaque
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “For surveillance of the antimicro-
bial effectiveness of treatment, swabs were
taken on 3 consecutive days after the end
of the 14-day observation period...... The
assessor was blinded to the treatment given.
”
Comment: assessor was blinded to treat-
ment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no specific quote but all ran-
domised patients were included in the anal-
ysis
Selective reporting (reporting bias) Low risk Comment: no specific quote but appears
all outcomes discussed in Methods section
appear in results
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Wild 2012 (Continued)
Other bias Low risk Comment: no evidence of other sources of
bias.
Yapucu Güne 2007
Methods Country where data collected: Turkey
Parallel group RCT
Unit of randomisation: participant
Unit of analysis: ulcer
Duration: 5 weeks
Participants Inclusion criteria: patients aged ≥ 18 years with stage II/III pressure ulcers
Exclusion criteria: patients with diabetes or terminal illness were excluded
N: 27 participants with ≥ 51 ulcers (randomised); 26 participants with 50 ulcers (anal-
ysed)
N males: 9/15 vs 8/11*
Mean age (years): 65.8 vs 66.6
Ulcer stage: 96% of ulcers in both groups were stage III
Ulcer location: sacral 12 vs 12; shoulder 3 vs 4; trochanter 5 vs 2; heel 5 vs 7
Interventions Intervention arm 1: honey
Intervention arm 2: ethoxy-diaminoacridine plus nitrofurazone dressings
Cointerventions: preventative regimen of turning/repositioning and pressure-relieving
mattress
Outcomes Primary outcome: wound healing
Primary outcome: adverse events
Secondary outcome: changes in ulcer size
Notes *demographic data refers to patients included in analysis (1 patient died and was ex-
cluded)
Funding: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The authors completed a random-
ized parallel group evaluation comparing
honey dressing with an ethoxydiaminoacri-
dine plus nitrofurazone dressing for the
treatment of pressure ulcers.”
Comment: no further information on how
randomisation was carried out
Allocation concealment (selection bias) Unclear risk Comment: no information on methods
used to conceal allocation; quote above is
all the information provided
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Yapucu Güne 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The authors could not be blinded
to the treatment. Blinding would have re-
quired irrigation of the PU with sterile 0.
9% sodium chloride(NaCl) immediately
before an outcome assessor examined the
wound. They needed to identify the pres-
ence of exudate and slough, which could
not be done in a blinded study”
Comment: unblinded assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “75% of the patients (n = 27) we
approached met the inclusion criteria and
were enrolled in the study. Subsequently,
1 patient in the control group died. As a
result, the final analysis sample is drawn
from 26 patients”
Comment: 1 patient died, data from all
other patients was included in the analysis
Selective reporting (reporting bias) Low risk Comment: no specific quote but outcomes
discussed in methods were all reported
Other bias High risk Comment: no specific quote: randomisa-
tionwas conducted at a patient level but the
analysiswas carried out at the level of the ul-
cer; it did not appear that paired data (mul-
tiple ulcers from individual participants)
were accounted for in the analysis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anzai 1989 Wrong population: fewer than 75% patients with PU
Baker 1981 Not a randomised controlled trial
Bale 2004 Wrong population: minority of patients with PU
Bazzigaluppi 1991 Not a randomised controlled trial
Becker 1984 Not a randomised controlled trial
Beele 2010 Wrong population: minority of patients with PU
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(Continued)
Boykin 1989 Not a randomised controlled trial
Chirwa 2010 Wrong population: minority of patients with PU
Colombo 1993 Wrong population: minority of patients with PU
de Laat 2011 Wrong intervention
Della Marchina 1997 Not a randomised controlled trial
Gerding 1992 Wrong population: mixed stage 1 and higher PU stage 2+ under 75%
Gorse 1987 Use of antiseptic/antibiotic not the only difference between intervention arms
Hartman 2002 Not a randomised controlled trial
Helaly 1988 Wrong population: minority of patients with PU
Ishibashi 1996 Wrong population: fewer than 75% patients with PU
Itani 2010 Wrong population: minority of patients with PU
Kim 1996 Wrong population: mixed stage 1 and higher PU stage 2+ under 75%
Konychev 2013 Wrong population: minority of patients with PU
Kuroyanagi 1995 Not a randomised controlled trial
Lazareth 2012 Wrong population, not PU
Lee 2014 Wrong population: minority of patients with PU
LeVasseur 1991 Wrong intervention
Meaume 2005 Wrong population: minority of patients with PU
Motta 2004 Wrong population: minority of patients with PU
Munter 2006 Wrong population: minority of patients with PU
Parish 1984a Wrong population: minority of patients with PU
Parish 1984b Wrong population: minority of patients with PU
Rhodes 2001 Quasi-randomised
Robson 1999 Wrong intervention
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(Continued)
Romanelli 2008 Wrong population: minority of patients with PU
Saha 2012 Quasi-randomised
Saydak 1990 Not a randomised controlled trial
Serra 2005 Not a randomised controlled trial
Shrivastava 2011 Wrong comparator
Sibbald 2011 Wrong population: not PU
Stevens 2002 Wrong population: minority of patients with PU
Thomas 1998 Wrong intervention
Trial 2010 Wrong population: minority of patients with PU
van der Cammen 1987 Wrong population: patients at risk of pressure sores
Wang 2014 Wrong intervention
Weheida 1991 Wrong population: Stage 1 pressure ulcers
Worsley 1991 Wrong population: minority of patients with PU
Yastrub 2005 No relevant outcomes
Yura 1984 Wrong population: fewer than 75% patients with PU
Zeron 2007 Wrong intervention
Characteristics of studies awaiting assessment [ordered by study ID]
Bigolari 1991
Methods RCT
Participants N = 28 patients
Interventions Intervention arm 1: cadexomer iodine
Intervention arm 2: standard care
Outcomes Primary outcome: adverse events
Secondary outcome: wound area reduction
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Bigolari 1991 (Continued)
Notes trial published in Italian, English abstract
Goldmeier 1997
Methods RCT
Participants N = 27 patients
Patients with heart disease and pressure ulcers
Interventions Intervention arm 1: medium chain triglycerides with essential fatty acids
Intervention arm 2: povidone iodine
Outcomes Secondary outcome: wound area reduction
Notes Trial published in Portuguese (English translation of abstract obtained); full paper not yet obtained
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D A T A A N D A N A L Y S E S
Comparison 1. Povidone iodine versus hydrocolloid (granuflex)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 76 Risk Ratio (M-H, Fixed, 95% CI) 0.9 [0.41, 1.96]
Comparison 2. Povidone iodine versus hydrogel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.43, 0.97]
Comparison 3. Povidone iodine versus saline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infection (eradication) 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.48, 1.37]
Comparison 4. Povidone iodine versus protease-modulating matrix treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.62, 0.98]
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Comparison 5. Cadexomer iodine versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 38 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.80, 45.20]
2 Adverse events 1 27 Risk Ratio (M-H, Fixed, 95% CI) 10.27 [0.62, 169.16]
3 Reduction in wound area 1 27 Mean Difference (IV, Fixed, 95% CI) 18.80 [-5.65, 43.25]
4 Pain 1 26 Mean Difference (IV, Fixed, 95% CI) -4.4 [-10.82, 2.02]
Comparison 6. Pine resin salve versus hydrocolloid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 45 Risk Ratio (M-H, Fixed, 95% CI) 2.83 [1.14, 7.05]
2 Infection 1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.79]
Comparison 7. Iodine sugar versus lysozyme
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 141 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.60, 2.37]
2 Adverse events 1 141 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.03, 3.00]
3 Serious adverse events 1 141 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.72]
4 Reduction in wound area by at
least 25%
1 121 Risk Ratio (M-H, Random, 95% CI) 1.33 [1.02, 1.73]
5 Improvement in wound
infection status (to highest
level)
1 122 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.01, 2.68]
Comparison 8. Iodine sugar versus gentian violet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in wound area 1 19 Mean Difference (IV, Fixed, 95% CI) 11.10 [-5.66, 27.86]
2 Change in resistance (eradication
of MRSA)
1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.53, 1.30]
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Comparison 9. Polyhexanide dressing versus polyhexanide swabs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in resistance (eradication
of MRSA)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [1.02, 2.13]
2 Pain 1 30 Mean Difference (IV, Fixed, 95% CI) -2.03 [-2.66, -1.40]
Comparison 10. Povidone iodine versus silver sulfadiazine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infection (eradication) 1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.41, 1.01]
Comparison 13. Honey versus ethoxy-diaminoacridine plus nitrofurazone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete wound healing 1 51 Risk Ratio (M-H, Fixed, 95% CI) 11.42 [0.66, 196.40]
Comparison 14. Silver sulfadiazine versus saline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infection (eradication) 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.94, 1.69]
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Analysis 1.1. Comparison 1 Povidone iodine versus hydrocolloid (granuflex), Outcome 1 Complete wound
healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 1 Povidone iodine versus hydrocolloid (granuflex)
Outcome: 1 Complete wound healing
Study or subgroup Povidone iodine Hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barrois 1993 9/38 10/38 100.0 % 0.90 [ 0.41, 1.96 ]
Total (95% CI) 38 38 100.0 % 0.90 [ 0.41, 1.96 ]
Total events: 9 (Povidone iodine), 10 (Hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hydrocolloid Favours povidone iodine
Analysis 2.1. Comparison 2 Povidone iodine versus hydrogel, Outcome 1 Complete wound healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 2 Povidone iodine versus hydrogel
Outcome: 1 Complete wound healing
Study or subgroup
Favours
povidone
iodine Favours hydrogel Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaya 2005 13/24 21/25 100.0 % 0.64 [ 0.43, 0.97 ]
Total (95% CI) 24 25 100.0 % 0.64 [ 0.43, 0.97 ]
Total events: 13 (Favours povidone iodine), 21 (Favours hydrogel)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hydrogel Favours povidone iodine
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Analysis 3.1. Comparison 3 Povidone iodine versus saline, Outcome 1 Infection (eradication).
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 3 Povidone iodine versus saline
Outcome: 1 Infection (eradication)
Study or subgroup Povidone iodine Saline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kucan 1981 7/11 11/14 100.0 % 0.81 [ 0.48, 1.37 ]
Total (95% CI) 11 14 100.0 % 0.81 [ 0.48, 1.37 ]
Total events: 7 (Povidone iodine), 11 (Saline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours saline Favours povidone iodine
Analysis 4.1. Comparison 4 Povidone iodine versus protease-modulating matrix treatment, Outcome 1
Complete wound healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 4 Povidone iodine versus protease-modulating matrix treatment
Outcome: 1 Complete wound healing
Study or subgroup Povidone iodine Protease-modulating Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nisi 2005 28/40 36/40 100.0 % 0.78 [ 0.62, 0.98 ]
Total (95% CI) 40 40 100.0 % 0.78 [ 0.62, 0.98 ]
Total events: 28 (Povidone iodine), 36 (Protease-modulating)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.030)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PMM Favours povidone iodine
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Analysis 5.1. Comparison 5 Cadexomer iodine versus standard care, Outcome 1 Complete wound healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 5 Cadexomer iodine versus standard care
Outcome: 1 Complete wound healing
Study or subgroup cadexomer iodine standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Moberg 1983 6/19 1/19 100.0 % 6.00 [ 0.80, 45.20 ]
Total (95% CI) 19 19 100.0 % 6.00 [ 0.80, 45.20 ]
Total events: 6 (cadexomer iodine), 1 (standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard care Favours cadexomer iodine
Analysis 5.2. Comparison 5 Cadexomer iodine versus standard care, Outcome 2 Adverse events.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 5 Cadexomer iodine versus standard care
Outcome: 2 Adverse events
Study or subgroup Cadexomer iodine Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Moberg 1983 5/14 0/13 100.0 % 10.27 [ 0.62, 169.16 ]
Total (95% CI) 14 13 100.0 % 10.27 [ 0.62, 169.16 ]
Total events: 5 (Cadexomer iodine), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours cadexomer iodine Favours standard care
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Analysis 5.3. Comparison 5 Cadexomer iodine versus standard care, Outcome 3 Reduction in wound area.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 5 Cadexomer iodine versus standard care
Outcome: 3 Reduction in wound area
Study or subgroup cadexomer iodine Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moberg 1983 14 76.2 (30.6816) 13 57.4 (33.8922) 100.0 % 18.80 [ -5.65, 43.25 ]
Total (95% CI) 14 13 100.0 % 18.80 [ -5.65, 43.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours standard care Favours cadexomer iodine
Analysis 5.4. Comparison 5 Cadexomer iodine versus standard care, Outcome 4 Pain.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 5 Cadexomer iodine versus standard care
Outcome: 4 Pain
Study or subgroup Cadexomer Iodine Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Moberg 1983 13 3.1 (6.1294) 13 7.5 (10.0955) 100.0 % -4.40 [ -10.82, 2.02 ]
Total (95% CI) 13 13 100.0 % -4.40 [ -10.82, 2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours cadexomer iodine Favours standard care
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Analysis 6.1. Comparison 6 Pine resin salve versus hydrocolloid, Outcome 1 Complete wound healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 6 Pine resin salve versus hydrocolloid
Outcome: 1 Complete wound healing
Study or subgroup Pine resin salve Hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sipponen 2008 17/27 4/18 100.0 % 2.83 [ 1.14, 7.05 ]
Total (95% CI) 27 18 100.0 % 2.83 [ 1.14, 7.05 ]
Total events: 17 (Pine resin salve), 4 (Hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hydrocolloid Favours pine resin
Analysis 6.2. Comparison 6 Pine resin salve versus hydrocolloid, Outcome 2 Infection.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 6 Pine resin salve versus hydrocolloid
Outcome: 2 Infection
Study or subgroup Pine resin salve Hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sipponen 2008 1/18 1/18 100.0 % 1.00 [ 0.07, 14.79 ]
Total (95% CI) 18 18 100.0 % 1.00 [ 0.07, 14.79 ]
Total events: 1 (Pine resin salve), 1 (Hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pine resin Favours hydrocolloid
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Analysis 7.1. Comparison 7 Iodine sugar versus lysozyme, Outcome 1 Complete wound healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 7 Iodine sugar versus lysozyme
Outcome: 1 Complete wound healing
Study or subgroup Iodine sugar Lysozome ointment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Imamura 1989 15/72 12/69 100.0 % 1.20 [ 0.60, 2.37 ]
Total (95% CI) 72 69 100.0 % 1.20 [ 0.60, 2.37 ]
Total events: 15 (Iodine sugar), 12 (Lysozome ointment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours lysozome Favours iodine sugar
Analysis 7.2. Comparison 7 Iodine sugar versus lysozyme, Outcome 2 Adverse events.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 7 Iodine sugar versus lysozyme
Outcome: 2 Adverse events
Study or subgroup Iodine sugar Lysozome ointment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Imamura 1989 1/72 3/69 100.0 % 0.32 [ 0.03, 3.00 ]
Total (95% CI) 72 69 100.0 % 0.32 [ 0.03, 3.00 ]
Total events: 1 (Iodine sugar), 3 (Lysozome ointment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours iodine sugar Favours lysozome
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Analysis 7.3. Comparison 7 Iodine sugar versus lysozyme, Outcome 3 Serious adverse events.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 7 Iodine sugar versus lysozyme
Outcome: 3 Serious adverse events
Study or subgroup Iodine sugar Lysozome ointment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Imamura 1989 0/72 1/69 100.0 % 0.32 [ 0.01, 7.72 ]
Total (95% CI) 72 69 100.0 % 0.32 [ 0.01, 7.72 ]
Total events: 0 (Iodine sugar), 1 (Lysozome ointment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours iodine sugar Favours lysozome
Analysis 7.4. Comparison 7 Iodine sugar versus lysozyme, Outcome 4 Reduction in wound area by at least
25%.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 7 Iodine sugar versus lysozyme
Outcome: 4 Reduction in wound area by at least 25%
Study or subgroup Iodine sugar Lysozome ointment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Imamura 1989 46/61 34/60 100.0 % 1.33 [ 1.02, 1.73 ]
Total (95% CI) 61 60 100.0 % 1.33 [ 1.02, 1.73 ]
Total events: 46 (Iodine sugar), 34 (Lysozome ointment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours lysozome ointment Favours iodine sugar
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Analysis 7.5. Comparison 7 Iodine sugar versus lysozyme, Outcome 5 Improvement in wound infection
status (to highest level).
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 7 Iodine sugar versus lysozyme
Outcome: 5 Improvement in wound infection status (to highest level)
Study or subgroup Iodine sugar Lysozome ointment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Imamura 1989 28/61 17/61 100.0 % 1.65 [ 1.01, 2.68 ]
Total (95% CI) 61 61 100.0 % 1.65 [ 1.01, 2.68 ]
Total events: 28 (Iodine sugar), 17 (Lysozome ointment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours lysozome ointment Favours iodine sugar
Analysis 8.1. Comparison 8 Iodine sugar versus gentian violet, Outcome 1 Change in wound area.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 8 Iodine sugar versus gentian violet
Outcome: 1 Change in wound area
Study or subgroup Iodine sugar Gentian violet
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Toba 1997 11 55.7 (24) 8 44.6 (12.9) 100.0 % 11.10 [ -5.66, 27.86 ]
Total (95% CI) 11 8 100.0 % 11.10 [ -5.66, 27.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours iodine sugar Favours gentian violet
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Analysis 8.2. Comparison 8 Iodine sugar versus gentian violet, Outcome 2 Change in resistance
(eradication of MRSA).
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 8 Iodine sugar versus gentian violet
Outcome: 2 Change in resistance (eradication of MRSA)
Study or subgroup Iodine sugar Gentian violet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Toba 1997 8/11 7/8 100.0 % 0.83 [ 0.53, 1.30 ]
Total (95% CI) 11 8 100.0 % 0.83 [ 0.53, 1.30 ]
Total events: 8 (Iodine sugar), 7 (Gentian violet)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours gentian violet Favours iodine sugar
Analysis 9.1. Comparison 9 Polyhexanide dressing versus polyhexanide swabs, Outcome 1 Change in
resistance (eradication of MRSA).
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 9 Polyhexanide dressing versus polyhexanide swabs
Outcome: 1 Change in resistance (eradication of MRSA)
Study or subgroup Polyhexanide dressing Polyhexanide swabs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wild 2012 15/15 10/15 100.0 % 1.48 [ 1.02, 2.13 ]
Total (95% CI) 15 15 100.0 % 1.48 [ 1.02, 2.13 ]
Total events: 15 (Polyhexanide dressing), 10 (Polyhexanide swabs)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours swabs Favours dressing
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Analysis 9.2. Comparison 9 Polyhexanide dressing versus polyhexanide swabs, Outcome 2 Pain.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 9 Polyhexanide dressing versus polyhexanide swabs
Outcome: 2 Pain
Study or subgroup Polyhexanide dressing Polyhexanide swabs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wild 2012 15 1.3 (0.36) 15 3.33 (1.2) 100.0 % -2.03 [ -2.66, -1.40 ]
Total (95% CI) 15 15 100.0 % -2.03 [ -2.66, -1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.28 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours dressing Favours swabs
Analysis 10.1. Comparison 10 Povidone iodine versus silver sulfadiazine, Outcome 1 Infection (eradication).
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 10 Povidone iodine versus silver sulfadiazine
Outcome: 1 Infection (eradication)
Study or subgroup Povidone iodine Silver sulfadiazine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kucan 1981 7/11 15/15 100.0 % 0.65 [ 0.41, 1.01 ]
Total (95% CI) 11 15 100.0 % 0.65 [ 0.41, 1.01 ]
Total events: 7 (Povidone iodine), 15 (Silver sulfadiazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SSD Favours povidone iodine
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Analysis 13.1. Comparison 13 Honey versus ethoxy-diaminoacridine plus nitrofurazone, Outcome 1
Complete wound healing.
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 13 Honey versus ethoxy-diaminoacridine plus nitrofurazone
Outcome: 1 Complete wound healing
Study or subgroup Honey
Ethoxy-
diaminoacridine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yapucu G˙x00fc˙ne˙x015f˙ 2007 5/25 0/26 100.0 % 11.42 [ 0.66, 196.40 ]
Total (95% CI) 25 26 100.0 % 11.42 [ 0.66, 196.40 ]
Total events: 5 (Honey), 0 (Ethoxy-diaminoacridine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours E-D Favours Honey
Analysis 14.1. Comparison 14 Silver sulfadiazine versus saline, Outcome 1 Infection (eradication).
Review: Antibiotics and antiseptics for pressure ulcers
Comparison: 14 Silver sulfadiazine versus saline
Outcome: 1 Infection (eradication)
Study or subgroup Silver sulfadiazine Saline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kucan 1981 15/15 11/14 100.0 % 1.26 [ 0.94, 1.69 ]
Total (95% CI) 15 14 100.0 % 1.26 [ 0.94, 1.69 ]
Total events: 15 (Silver sulfadiazine), 11 (Saline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours saline Favours SSD
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A D D I T I O N A L T A B L E S
Table 1. Summary of outcome data
Study Interven-
tions
wound heal-
ing
adverse
events
Wound size
(change)
Infection
status
or resistance
(change)
Pain Resource
use
Costs
Barrois
1993
Povidone io-
dine
Hydrocol-
loid
9/38 vs 10/
38
0/38 vs 0/38 Dressings/
week
5.07 vs 2.43
(SD not re-
ported)
Chuang-
suwanich
2011
Silver mesh
Silver sulfa-
diazine
0/20 vs 0/20 20.1%
vs 34.6% re-
duction (SD
not
reported; N
= 20 in both
groups)
USD 263 vs
USD 1812
(SD not re-
ported)
Chuang-
suwanich
2013
Silver
alginate
Silver sulfa-
diazine
51.7% (N =
13) vs
44.27% (N
= 15) reduc-
tion (SD not
reported)
USD 377.
17
vsUSD467.
74 (SD not
reported)
Imamura
1989
Povidone io-
dine sugar
Lysozyme
ointment
15/72 vs 12/
69
1/72 vs 3/69 28/61 vs 17/
61 improved
Kaya 2005 Povidone io-
dine
Hydrogel
13/24 vs 21/
25 ulcers
Kucan 1981 Povidone io-
dine
Silver sulfa-
diazine
Saline
7/11 vs 15/
15 vs 11/14
resolved
Moberg
1983
Cadexomer
iodine
Standard
care
6/19 vs 1/19 5/14 vs 0/13
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Table 1. Summary of outcome data (Continued)
Nisi 2005 Povidone io-
dine
Protease-
modulating
matrix
28/40 vs 36/
40
76.2%
(SE 8.2; n
= 14) vs 57.
4% (SE 9.4;
n = 13) re-
duction
3.1 (SE 1.7)
vs 7.5 (SE 2.
8)
hospital
stay: 1164 vs
360 days
dressing use;
14 to 52 vs 6
to 15
Sipponen
2008
Spruce resin
salve
Hydrocol-
loid
17/27 vs 4/
18
1/18 vs 1/
18 infected/
resolved
Toba 1997 Povidone io-
dine sugar
Gentian vio-
let
44.3%
vs 55.4% re-
duction (de-
crease to 55.
7 (24.0)% vs
decrease to
44.6 (12.9)
%
8/11 vs 7/
8 no longer
MRSA
affected
Wild 2012 Polyhex-
anide dress-
ing
Polyhex-
anide swabs
15/15 vs 10/
15 no longer
MRSA
affected
1.3 (0.36) vs
3.33 (1.2)
Dressing
change time:
6 vs 25 min
(SD not re-
ported)
Yapucu
Güne 2007
Honey
Ethoxy-di-
aminoacri-
dine plus
nitrofura-
zone
5/25 vs 0/
≥26 ulcers
0/15 vs 0/11 56% vs 13%
reduc-
tion (SD not
reported)
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A P P E N D I C E S
Appendix 1. Search Strategies
The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)
#1 MeSH descriptor: [Anti-Infective Agents] explode all trees
#2 MeSH descriptor: [Penicillins] explode all trees
#3 MeSH descriptor: [Cephalosporins] explode all trees
#4 MeSH descriptor: [Aminoglycosides] explode all trees
#5 MeSH descriptor: [Quinolones] explode all trees
#6 MeSH descriptor: [Clindamycin] explode all trees
#7 MeSH descriptor: [Metronidazole] explode all trees
#8 MeSH descriptor: [Trimethoprim] explode all trees
#9 MeSH descriptor: [Mupirocin] explode all trees
#10 MeSH descriptor: [Neomycin] explode all trees
#11 MeSH descriptor: [Fusidic Acid] explode all trees
#12 MeSH descriptor: [Framycetin] explode all trees
#13 MeSH descriptor: [Polymyxins] explode all trees
#14 MeSH descriptor: [Chlortetracycline] explode all trees
#15 (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin
or metronidazole or trimethoprim or mupirocin or ”pseudomonic acid“ or neomycin or ”fusidic acid“ or framycetin or polymyxin* or
chlortetracycline):ti,ab,kw
#16 MeSH descriptor: [Antisepsis] explode all trees
#17 antiseptic*:ti,ab,kw
#18 MeSH descriptor: [Soaps] explode all trees
#19 MeSH descriptor: [Iodophors] explode all trees
#20 MeSH descriptor: [Chlorhexidine] explode all trees
#21 MeSH descriptor: [Alcohols] explode all trees
#22 MeSH descriptor: [Hydrogen Peroxide] explode all trees
#23 MeSH descriptor: [Benzoyl Peroxide] explode all trees
#24 MeSH descriptor: [Gentian Violet] explode all trees
#25 MeSH descriptor: [Hypochlorous Acid] explode all trees
#26 MeSH descriptor: [Hexachlorophene] explode all trees
#27 MeSH descriptor: [Potassium Permanganate] explode all trees
#28 MeSH descriptor: [Silver] explode all trees
#29 MeSH descriptor: [Silver Sulfadiazine] explode all trees
#30 MeSH descriptor: [Honey] explode all trees
#31 (soap or soaps or iodophor* or povidone or iodine or chlorhexidine or betadine or ”alcohol“ or disinfectant* or ”hydrogen peroxide“
or ”benzoyl peroxide“ or ”gentian violet“ or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or ”potassium
permanganate“ or ”silver sulfadiazine“ or ”silver sulphadiazine“ or honey*):ti,ab,kw
#32 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#33 MeSH descriptor: [Pressure Ulcer] explode all trees
#34 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#35 (decubitus next (ulcer* or sore*)):ti,ab,kw
#36 ((bed next sore*) or bedsore):ti,ab,kw
#37 #33 or #34 or #35 or #36
#38 #32 and #37
Ovid MEDLINE
1 exp Anti-Infective Agents/
2 exp Penicillins/
3 exp Cephalosporins/
4 exp Aminoglycosides/
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5 exp Quinolones/
6 exp Clindamycin/
7 exp Metronidazole/
8 exp Trimethoprim/
9 exp Mupirocin/
10 exp Neomycin/
11 exp Fusidic Acid/
12 exp Framycetin/
13 exp Polymyxins/
14 exp Chlortetracycline/
15 (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin
or metronidazole or trimethoprim or mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or polymyxin* or
chlortetracycline).ti,ab.
16 exp Antisepsis/
17 antiseptic*.ti,ab.
18 exp Soaps/
19 exp Iodophors/
20 exp Chlorhexidine/
21 exp Alcohols/
22 exp Hydrogen Peroxide/
23 exp Benzoyl Peroxide/
24 exp Gentian Violet/
25 exp Hypochlorous Acid/
26 exp Hexachlorophene/
27 exp Potassium Permanganate/
28 exp Silver/
29 exp Silver Sulfadiazine/
30 exp Honey/
31 (soap*1 or iodophor* or povidone or iodine or chlorhexidine or betadine or alcohol*1 or disinfectant* or hydrogen peroxide or
benzoyl peroxide or gentian violet or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium permanganate
or silver sulfadiazine or silver sulphadiazine or honey*).ti,ab.
32 or/1-31
33 exp Pressure Ulcer/
34 (pressure adj (ulcer* or sore* or injur*)).tw.
35 (decubitus adj (ulcer* or sore*)).tw.
36 (bedsore* or bed sore*).tw.
37 or/33-36
38 32 and 37
39 randomized controlled trial.pt.
40 controlled clinical trial.pt.
41 randomi?ed.ab.
42 placebo.ab.
43 clinical trials as topic.sh.
44 randomly.ab.
45 trial.ti.
46 or/39-45
47 exp animals/ not humans.sh.
48 46 not 47
49 38 and 48
Ovid EMBASE
1 exp Antiinfective Agent/
2 exp Penicillin G/
3 exp Cephalosporin/
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4 exp Aminoglycoside/
5 exp Quinolone/
6 exp Clindamycin/
7 exp Metronidazole/
8 exp Trimethoprim/
9 exp Pseudomonic Acid/
10 exp Neomycin/
11 exp Fusidic Acid/
12 exp Framycetin/
13 exp Polymyxin/
14 exp Chlortetracycline/
15 (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin
or metronidazole or trimethoprim or mupirocin or neomycin or fusidic acid or framycetin or polymyxin* or chlortetracycline).ti,ab.
16 exp antisepsis/
17 antiseptic*.ti,ab.
18 exp Soap/
19 exp Iodophor/
20 exp Chlorhexidine/
21 exp Alcohol/
22 exp Hydrogen Peroxide/
23 exp Benzoyl Peroxide/
24 exp Gentian Violet/
25 exp Hypochlorous Acid/
26 exp Hexachlorophene/
27 exp Potassium Permanganate/
28 exp Silver/
29 exp Silver Sulfadiazine/
30 exp Honey/
31 (soap*1 or iodophor* or povidone or iodine or chlorhexidine or betadine or alcohol*1 or disinfectant* or hydrogen peroxide or
benzoyl peroxide or gentian violet or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium permanganate
or silver sulfadiazine or silver sulphadiazine or honey*).ti,ab.
32 or/1-31
33 exp decubitus/
34 (pressure adj (ulcer* or sore* or injur*)).tw.
35 (decubitus adj (ulcer* or sore*)).tw.
36 (bedsore* or bed sore*).tw.
37 or/33-36
38 32 and 37
39 Randomized controlled trials/
40 Single-Blind Method/
41 Double-Blind Method/
42 Crossover Procedure/
43 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
44 (doubl* adj blind*).ti,ab.
45 (singl* adj blind*).ti,ab.
46 or/39-45 (1487429)
47 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
48 human/ or human cell/
49 and/47-48
50 47 not 49
51 46 not 50
52 38 and 51
EBSCO CINAHL Plus
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S45 S32 AND S44
S44 S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43
S43 MH ”Quantitative Studies“
S42 TI placebo* or AB placebo*
S41 MH ”Placebos“
S40 TI random* allocat* or AB random* allocat*
S39 MH ”Random Assignment“
S38 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S37 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S36 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S35 TI clinic* N1 trial* or AB clinic* N1 trial*
S34 PT Clinical trial
S33 MH ”Clinical Trials+“
S32 S26 AND S31
S31 S27 OR S28 OR S29 OR S30
S30 TI ( bedsore* or (bed n1 sore*) ) OR AB ( bedsore* or (bed n1 sore*) )
S29 TI ( decubitus n1 (ulcer* or sore*) ) OR AB ( decubitus n1 (ulcer* or sore*) )
S28 TI ( pressure n1 (ulcer* or sore* or injur*) ) OR AB ( pressure n1 (ulcer* or sore* or injur*) )
S27 (MH ”Pressure Ulcer+“)
S26 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
or S21 or S22 or S23 or S24 or S25
S25 TI ( soap* or iodophor* or povidone or iodine or chlorhexidine or betadine or alcohol* or disinfectant* or hydrogen peroxide
or benzoyl peroxide or gentian violet or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium perman-
ganate or silver sulfadiazine or silver sulphadiazine or honey*) or AB ( soap* or iodophor* or povidone or iodine or chlorhexidine or
betadine or alcohol* or disinfectant* or hydrogen peroxide or benzoyl peroxide or gentian violet or hypochlorit* or eusol or dakin* or
hexachlorophene or benzalkonium or potassium permanganate or silver sulfadiazine or silver sulphadiazine or honey*)
S24 (MH ”Honey“)
S23 (MH ”Silver Sulfadiazine“)
S22 (MH ”Silver“)
S21 (MH ”Hexachlorophene“)
S20 (MH ”Gentian Violet“)
S19 (MH ”Hydrogen Peroxide“)
S18 (MH ”Alcohols+“)
S17 (MH ”Chlorhexidine“)
S16 (MH ”Povidone-Iodine“)
S15 (MH ”Iodine“)
S14 (MH ”Soaps“)
S13 TI antiseptic*
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11TI ( antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or quinolone* or clindamycin
or metronidazole or trimethoprim or mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or polymyxin*
or chlortetracycline ) or AB ( antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or
quinolone* or clindamycin or metronidazole or trimethoprim or mupirocin or pseudomonic acid or neomycin or fusidic acid or
framycetin or polymyxin* or chlortetracycline)
S10 (MH ”Polymyxins+“)
S9 (MH ”Neomycin“)
S8 (MH ”Mupirocin“)
S7 (MH ”Trimethoprim+“)
S6 (MH ”Metronidazole“)
S5 (MH ”Clindamycin“)
S4 (MH ”Aminoglycosides+“)
S3 (MH ”Cephalosporins+“)
S2 (MH ”Penicillins+“)
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S1 (MH ”Antiinfective Agents+“)
Appendix 2. Risk of bias assessment (individually randomised controlled trials)
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process, such as referring to a random number table; using
a computer random number generator; tossing a coin; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example sequence generated by odd or even date of birth; sequence generated by some rule based
on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear risk of bias
Insufficient information about the sequence generation process provided to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate
safeguards (e.g. if envelopes were unsealed or non-opaque or were not sequentially numbered); alternation or rotation; date of birth;
case record number; any other explicitly unconcealed procedure.
Unclear risk of bias
Insufficient information provided to permit judgement of low or high risk of bias. This is usually the case if the method of concealment
is not described or is not described in sufficient detail to allow a definitive judgement, for example if the use of assignment envelopes
is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding (participants, personnel and outcome assessors) - was knowledge of the allocated interventions
adequately prevented during the study?
Low risk of bias
Any one of the following.
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• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others is unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others is likely to introduce bias.
Unclear risk of bias
Either of the following.
• Insufficient information provided to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes is not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following.
• Reason for missing outcome data likely to be related to true outcome, with imbalance in numbers or reasons for missing data
across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes is enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear risk of bias
Either of the following.
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
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5. Are reports of the study free of the suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the
review have been reported in the prespecified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were prespecified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following.
• Not all of the study’s prespecified primary outcomes have been reported.
• One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not prespecified.
• One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear risk of bias
Insufficient information provided to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into
this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear risk of bias
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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Appendix 3. Risk of bias assessment for cluster-randomised controlled trials
In cluster-randomised trials, particular biases to consider include:
• recruitment bias;
• baseline imbalance;
• loss of clusters;
• incorrect analysis; and
• comparability with individually randomised trials.
Recruitment bias: can occur when individuals are recruited to the trial after the clusters have been randomised, as the knowledge of
whether each cluster is an ’intervention’ or ’control’ cluster could affect the types of participants recruited.
Baseline imbalance: cluster-randomised trials often randomise all clusters at once, so lack of concealment of an allocation sequence
should not usually be an issue. However, because small numbers of clusters are randomised, there is a possibility of chance baseline
imbalance between the randomised groups, in terms of either the clusters or the individuals. Although this is not a form of bias as such,
the risk of baseline differences can be reduced by using stratified or pair-matched randomisation of clusters. Reporting of the baseline
comparability of clusters, or statistical adjustment for baseline characteristics, can help reduce concern about the effects of baseline
imbalance.
Loss of clusters: occasionally complete clusters are lost from a trial, and have to be omitted from the analysis. Just as for missing
outcome data in individually randomised trials, this may lead to bias. In addition, missing outcomes for individuals within clusters
may also lead to a risk of bias in cluster randomised trials.
Incorrect analysis: many cluster-randomised trials are analysed by incorrect statistical methods that do not take the clustering into
account. Such analyses create a ’unit of analysis error’ and produce over-precise results (the standard error of the estimated intervention
effect is too small) and P values that are too small. They do not lead to biased estimates of effect. However, if they remain uncorrected,
they will receive too much weight in a meta-analysis.
Comparability with individually randomised trials: in a meta-analysis that includes both cluster-randomised and individually
randomised trials, or including cluster-randomised trials with different types of clusters, possible differences between the intervention
effects being estimated need to be considered. For example, in a vaccine trial of infectious diseases, a vaccine applied to all individuals
in a community would be expected to be more effective than a vaccine applied to only half the people. Another example is provided by
a Cochrane review of hip protectors (Hahn 2005), where cluster trials showed a large positive effect, whereas individually randomised
trials did not show any clear benefit. One possibility is that there was a ’herd effect’ in the cluster-randomised trials (which were often
performed in nursing homes, where compliance with using the protectors may have been enhanced). In general, such ’contamination’
would lead to underestimates of effect. Thus, if an intervention effect is still demonstrated despite contamination in those trials that
were not cluster-randomised, a confident conclusion about the presence of an effect can be drawn. However, the size of the effect is
likely to be underestimated. Contamination and ’herd effects’ may be different for different types of cluster.
Appendix 4. Glossary of intervention and comparator terms
Cadexomer iodine is a compound of iodine which is used as an antiseptic. Dressings impregnated with cadexomer iodine release free
iodine during use.
Ethoxy-diaminoacridine is derived from Ethacridine lactate and is used as an antiseptic.
Gentian violet is an antiseptic and also a dye.
Povidone iodine is a compound of iodine which is used as an antiseptic. Povidone iodine-impregnated dressings release free iodine
when exposed to wound exudate.
Protease-modulating matrix: Protease-modulating dressings alter the activity of enzymes which act to break down proteins in the wound.
Hydrocolloid: Hydrocolloid dressings contain gel-forming agents in an adhesive compound laminated onto a flexible, water-resistant
outer layer (film or foam backing). Some formulations contain an alginate to increase absorption capabilities. When in contact with
the wound surface they form a gel to provide a moist environment.
Hydrogel: Hydrogel dressings contain a large amount of water that keeps ulcers moist rather than letting them become dry.
Lysozyme ointment is an ointment containing lysozyme, an enzyme which has antibacterial properties.
Nitrofurazone: a form of Nitrofural, a compound used as an antibiotic, most commonly in the form of ointments.
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Where participants with stage II and above pressure ulcers were a subgroup of randomised individuals we had planned to analyse the
subgroup of participants where data could be obtained, or to analyse the whole trial data where the relevant participants made up
at least 75% of the trial population and separate data were not available. Instead of this we have included only trials where relevant
participants constituted at least 75% of participants and have analysed the data from the whole trial population. We also carried out a
GRADE assessment on all eligible outcomes where possible, rather than limiting this to wound healing, adverse effects and changes in
infection status. This allows a more complete evaluation of the quality of the evidence base.
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